[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 199
1. Kim BJ, Kim DW, Kim SW, Han DH, Kim DY, Rhee CS, Lee CH: Endoscopic versus traditional craniofacial resection for patients with sinonasal tumors involving the anterior skull base. Clin Exp Otorhinolaryngol; 2008 Sep;1(3):148-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic versus traditional craniofacial resection for patients with sinonasal tumors involving the anterior skull base.
  • OBJECTIVES: With the advent of microdebriders and image guidance systems, endoscope-assisted surgery is now more widely used for the treatment of tumors involving the base of the skull.
  • The aim of this study was to analyze the clinical features of tumors involving the anterior skull base and to evaluate the treatment outcomes according to the surgical approach, which included the traditional craniofacial resection (TCFR) and the endoscopic craniofacial resection with craniotomy (ECFR).
  • RESULTS: The number of malignant and benign lesions was 40 and 6 cases respectively.
  • The most common diagnosis was olfactory neuroblastoma occurring in 41% of the cases followed by squamous cell carcinoma and malignant melanoma.
  • Thirty-six patients underwent TCFR, while ECFR was performed with or without adjunctive chemotherapy or radiotherapy in 10 patients.
  • The overall five-year survival rate for patients with malignant tumors of the anterior skull base was 47.4%.
  • Out of 19 patients with olfactory neuroblastomas, 10 patients had TCFR and six among them died of their disease.
  • Nine patients underwent ECFR, and none of them died of their disease.
  • CONCLUSION: The ECFR may be considered as an alternative option for the treatment of selected tumors with anterior skull base invasion.
  • This approach offers the advantages of avoiding facial incisions with comparable treatment results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Rhinol. 2007 Jan-Feb;21(1):89-94 [17283568.001]
  • [Cites] Laryngoscope. 2001 Mar;111(3):488-93 [11224781.001]
  • [Cites] Skull Base. 2006 Feb;16(1):15-8 [16880896.001]
  • [Cites] Laryngoscope. 2006 Jun;116(6):982-6 [16735899.001]
  • [Cites] Laryngorhinootologie. 2005 Dec;84(12):884-91 [16358197.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12(5):e4 [16119902.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):133-44, ix [15649504.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2257-60 [15484215.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] Am J Rhinol. 1999 Jul-Aug;13(4):303-10 [10485018.001]
  • [Cites] Am J Otolaryngol. 1997 Nov-Dec;18(6):431-3 [9395024.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80 [8837798.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Sep;118(9):913-7 [1503715.001]
  • [Cites] Am J Surg. 1988 Sep;156(3 Pt 1):187-90 [3421426.001]
  • [Cites] Otolaryngol Head Neck Surg. 1989 Dec;101(6):665-9 [2512555.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):352-8 [3661836.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):429-35 [3721885.001]
  • [Cites] Am J Rhinol. 2004 Jul-Aug;18(4):239-46 [15490571.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1123-42, ix [11728937.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1749-54 [17003718.001]
  • (PMID = 19434247.001).
  • [ISSN] 1976-8710
  • [Journal-full-title] Clinical and experimental otorhinolaryngology
  • [ISO-abbreviation] Clin Exp Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2671747
  • [Keywords] NOTNLM ; Endoscopic craniofacial resection / Nose neoplasms / Skull base
  •  go-up   go-down


2. Jimbo H, Kamata S, Miura K, Asamoto S, Tada S, Endo T, Masubuchi T, Nakamura N, Fushimi C: Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases. Neurol Med Chir (Tokyo); 2010 Jan;50(1):20-6; discussion 26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases.
  • Cancers of the paranasal sinuses and nasal cavity are the most common malignant tumors of the anterior and anterolateral skull base.
  • The treatment of these tumors affecting the skull base is complex due to the significant anatomical features.
  • En bloc resections using anterior skull base resection, orbital resection, middle fossa resection, and combined procedures of these three resections were performed.
  • Using a combination of adjuvant radiation and chemotherapy, we have achieved a 2-year disease-free survival rate of 90% in these cases.
  • We believe that the optimal management of such malignant tumors involves a multimodal and multidisciplinary team approach.
  • Here we present our recent institutional experience and treatment policy employed during the past 3 years.
  • [MeSH-major] Neurosurgical Procedures / methods. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base / pathology. Skull Base / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Cranial Fossa, Middle / anatomy & histology. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Drug Therapy / methods. Drug Therapy / statistics & numerical data. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Orbit / anatomy & histology. Orbit / pathology. Orbit / surgery. Osteotomy / contraindications. Osteotomy / methods. Paranasal Sinuses / anatomy & histology. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Patient Care Team. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / statistics & numerical data. Reconstructive Surgical Procedures / methods. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098020.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Sakashita T, Oridate N, Homma A, Nakamaru Y, Suzuki F, Hatakeyama H, Taki S, Sawamura Y, Yamamoto Y, Furuta Y, Fukuda S: Complications of skull base surgery: an analysis of 30 cases. Skull Base; 2009 Mar;19(2):127-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of skull base surgery: an analysis of 30 cases.
  • OBJECTIVES: To evaluate the risk factors for perioperative complications among patients undergoing craniofacial resection for the treatment of skull base tumors.
  • PARTICIPANTS: The study group comprised 29 patients with skull base tumors (22 malignant and 7 benign) who underwent 30 craniofacial resections at Hokkaido University Hospital between 1989 and 2006.
  • Of these cases, 21 had undergone prior treatment by radiation (16 cases), surgery (7 cases), or chemotherapy (1 case).
  • There was a significant difference between complication rates for cases with and without prior therapy (52.4% vs. 11.1%).
  • CONCLUSIONS: Craniofacial resection is a safe and effective treatment for skull base tumors.
  • However, additional care is required in patients with extended resection (especially dural) and those who have undergone prior therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1998 Mar;42(3):455-61; discussion 461-2 [9526977.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Nov;121(11):1253-7 [7576471.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] J Chronic Dis. 1974 Sep;27(7-8):387-404 [4436428.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Head Neck. 1999 Jan;21(1):12-20 [9890346.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):593-602 [10764003.001]
  • [Cites] Skull Base Surg. 1996;6(2):113-8 [17170985.001]
  • [Cites] Head Neck. 2005 Jun;27(6):445-51 [15825205.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Dec;123(12):1312-7 [9413360.001]
  • [Cites] Head Neck. 2003 Jul;25(7):515-20 [12808653.001]
  • (PMID = 19721768.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2671300
  • [Keywords] NOTNLM ; Complications / craniofacial resection / skull base surgery
  •  go-up   go-down


Advertisement
4. Patel SG, Singh B, Polluri A, Bridger PG, Cantu G, Cheesman AD, deSa GM, Donald P, Fliss D, Gullane P, Janecka I, Kamata SE, Kowalski LP, Kraus DH, Levine PA, dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer; 2003 Sep 15;98(6):1179-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial surgery for malignant skull base tumors: report of an international collaborative study.
  • BACKGROUND: Malignant tumors of the skull base are rare.
  • The current report was based on a large cohort that was analyzed retrospectively by an International Collaborative Study Group.
  • Definitive treatment prior to CFS had been administered in 59% of patients and included radiotherapy in 367 patients (28%), chemotherapy in 151 patients (12%), and surgery in 523 patients (40%).
  • The majority of tumors (87%) involved the anterior cranial fossa.
  • Squamous cell carcinoma (29%) and adenocarcinoma (16%) were the most common histologic types.
  • Adjuvant postoperative radiotherapy was received by 510 patients (39%), and chemotherapy was received by 57 patients (4%).
  • With a median follow-up of 25 months, the 5-year overall, disease-specific, and recurrence-free survival rates were 54%, 60%, and 53%, respectively.
  • The histology of the primary tumor, its intracranial extent, and the status of surgical margins were independent predictors of overall, disease-specific, and recurrence-free survival on multivariate analysis.
  • CONCLUSIONS: CFS is a safe and effective treatment option for patients with malignant tumors of the skull base.
  • The histology of the primary tumor, its intracranial extent, and the status of surgical margins are independent determinants of outcome.
  • [MeSH-major] Facial Bones / surgery. Skull / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. International Cooperation. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11630
  • (PMID = 12973841.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Tsai EC, Santoreneos S, Rutka JT: Tumors of the skull base in children: review of tumor types and management strategies. Neurosurg Focus; 2002 May 15;12(5):e1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the skull base in children: review of tumor types and management strategies.
  • Although many treatment strategies for skull base tumors in adults have been reported, relatively little has been reported regarding such therapies in the pediatric population.
  • Skull base tumors in children present a therapeutic challenge because of their unique pathological composition, the constraints of the maturing skull and brain, and the small size of the patients.
  • In this review, the authors examine the pediatric skull base lesions that occur in the anterior, middle, and posterior cranial base, focusing on unique pediatric tumors such as encepahalocele, fibrous dysplasia, esthesioneuroblastoma, craniopharyngioma, juvenile nasopharyngeal angiofibroma, cholesteatoma, chordoma, chondrosarcoma, and Ewing sarcoma.
  • They review management strategies that include radio- and chemotherapy, as well as surgical approaches with emphasis on the modifications and complications associated with the procedures as they apply in children.
  • Evidence for the advantages and limitations of radiotherapy, chemotherapy, and surgery as it pertains to the pediatric population will be examined.
  • With a working knowledge of skull base anatomy and special considerations of the developing craniofacial skeleton, neurosurgeons can treat skull base lesions in children with acceptable morbidity and mortality rates.
  • Outcomes in this population may be better than those in adults, in part because of the benign histopathology that frequently affects the pediatric skull base, as well as the plasticity of the maturing nervous system.
  • [MeSH-major] Skull Base Neoplasms
  • [MeSH-minor] Adolescent. Angiofibroma / radiotherapy. Angiofibroma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cholesteatoma / surgery. Chondrosarcoma / drug therapy. Chondrosarcoma / radiotherapy. Chondrosarcoma / surgery. Chordoma / surgery. Combined Modality Therapy. Craniopharyngioma / epidemiology. Craniopharyngioma / radiotherapy. Craniopharyngioma / surgery. Encephalocele / epidemiology. Encephalocele / surgery. Esthesioneuroblastoma, Olfactory / drug therapy. Esthesioneuroblastoma, Olfactory / mortality. Esthesioneuroblastoma, Olfactory / surgery. Female. Fibrous Dysplasia of Bone / pathology. Fibrous Dysplasia of Bone / surgery. Humans. Infant. Male. Neurosurgical Procedures / methods. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery. Pituitary Neoplasms / epidemiology. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Sarcoma, Ewing / therapy. Skull / pathology. Skull / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119897.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 143
  •  go-up   go-down


6. Lin PY, Chen WM, Hsieh YL, Chen WY, Chen TH: Orbital metastatic osteosarcoma. J Chin Med Assoc; 2005 Jun;68(6):286-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 15-year-old girl with right tibial osteosarcoma, diagnosed 22 months previously, developed right orbital and skull base metastases, with symptoms including painful protrusion of the right eyeball and severe visual impairment.
  • She underwent embolization of the metastatic tumor, local irradiation, and chemotherapy followed by intralesional resection of the mass because extensive involvement of the skull base precluded complete surgical resection.
  • The surgical specimen revealed a necrotic tumor similar to osteosarcoma.
  • Combined radiotherapy, chemotherapy and surgery can partially relieve symptoms, but cannot completely eradicate the tumors.
  • [MeSH-major] Orbital Neoplasms / secondary. Osteosarcoma / secondary
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Female. Humans. Visual Acuity

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984825.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


7. Hanbali F, Tabrizi P, Lang FF, DeMonte F: Tumors of the skull base in children and adolescents. J Neurosurg; 2004 Feb;100(2 Suppl Pediatrics):169-78
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the skull base in children and adolescents.
  • OBJECT: Published data obtained in children with tumors of the skull base are sparse.
  • In the majority of the available reports, the authors focus on the technical application of skull base approaches, but they contribute a paucity of information on the management of specific tumors, especially malignant skull base lesions.
  • The purposes of this report are to increase the collective experience with the treatment of these tumors and to identify successful management paradigms.
  • METHODS: The authors retrospectively reviewed the clinical records, pathological reports, and diagnostic images obtained in 24 children (< or = 19 years of age) with tumors arising from the cranial base in whom resection was part of their management between 1992 and 2002.
  • Surgery-related complications and outcomes were analyzed with regard to tumor type and surgical approach.
  • Tumors involved the anterior skull base in eight (33%), the middle skull base in 10 (42%), both the anterior and middle skull base in four (17%), and the posterior skull base in two patients (8%).
  • Benign lesions were discovered in 11 patients (46%) and malignant neoplasms in 13 (54%).
  • The tumors were most commonly of mesenchymal origin (21 [87.5%] of 24 tumors).
  • Thirty surgical procedures were performed using a number of skull base approaches.
  • A gross-total resection was achieved in 23 procedures (77%) and a subtotal resection in five (17%); a biopsy procedure was performed in one case; and the disease process could not be accessed in one case.
  • In nine patients (38%) the tumor recurred after a mean duration of 23 months.
  • CONCLUSIONS: Skull base tumors in children affect mainly the anterior and middle cranial fossa.
  • Sarcomas account for the majority of malignant tumors.
  • Treatment of skull base tumors in children and adolescents needs to be tailored to patient age, tumor location, and tumor type.
  • [MeSH-major] Craniotomy / methods. Postoperative Complications / etiology. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Diagnostic Imaging. Female. Humans. Infant. Male. Neurologic Examination. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / surgery. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Sarcoma / diagnosis. Sarcoma / secondary. Sarcoma / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14758945.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Wein RO, Popat SR, Doerr TD, Dutcher PO: Plasma cell tumors of the skull base: four case reports and literature review. Skull Base; 2002 May;12(2):77-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell tumors of the skull base: four case reports and literature review.
  • Four patients (mean age, 46 years; range, 28 to 60) with skull base plasmacytomas are presented along with a review of the literature examining the progression of anterior and central skull base plasma cell tumors to multiple myeloma.
  • Three patients presented with extensive local spread of tumor.
  • Two patients were diagnosed with multiple myeloma and treated with chemotherapy.
  • A partial or complete response to therapy was seen in all four cases.
  • Skull base plasma cell tumors are uncommon with only a limited number of published reports.
  • Patients with clivus, sphenoid, and petrous apex-based plasma cell tumors appear to have a higher risk of developing multiple myeloma than patients with plasma cell tumors involving the nasopharynx.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 May;108(5):495-500 [10335713.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1249-57 [10626148.001]
  • [Cites] J Otolaryngol. 2000 Aug;29(4):254-7 [11003081.001]
  • [Cites] Brain. 1954;77(1):61-81 [13160259.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Aug;101(8):665-8 [1497272.001]
  • [Cites] N Engl J Med. 1992 May 21;326(21):1417-24 [1569976.001]
  • [Cites] Am J Clin Pathol. 1987 Mar;87(3):342-55 [3825999.001]
  • [Cites] Clin Radiol. 1971 Jan;22(1):93-6 [5551340.001]
  • [Cites] Medicine (Baltimore). 1982 Sep;61(5):317-29 [6180279.001]
  • [Cites] Ann Ophthalmol. 1981 Apr;13(4):477-81 [7247194.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):218-21 [7616264.001]
  • [Cites] Otolaryngol Head Neck Surg. 1993 Nov;109(5):877-85 [8247569.001]
  • [Cites] Am J Ophthalmol. 1995 Dec;120(6):803-5 [8540559.001]
  • [Cites] Am J Hematol. 1996 May;52(1):60-1 [8638614.001]
  • [Cites] Br J Cancer. 1997;75(6):921-7 [9062417.001]
  • [Cites] Laryngoscope. 1997 Jun;107(6):741-6 [9185729.001]
  • [Cites] Am J Otolaryngol. 1998 May-Jun;19(3):203-8 [9617934.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Dec;119(6):614-8 [9852535.001]
  • [Cites] J Laryngol Otol. 1999 Feb;113(2):164-6 [10396570.001]
  • (PMID = 17167653.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1656911
  •  go-up   go-down


9. Völter C, Baier G, Hoppe F, Schwager K, Helms J: [Diagnosis, treatment and results of malignant skull base tumours]. Laryngorhinootologie; 2001 Sep;80(9):512-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis, treatment and results of malignant skull base tumours].
  • [Transliterated title] Diagnostik, Therapie und Ergebnisse in der Behandlung maligner Schädelbasistumoren1.
  • BACKGROUND: Malignant tumours of the cranial base are rare and present usually in advanced tumour stage due to the lack of early clinical symptoms.
  • PATIENTS AND METHODS: Sixty patients with malignant tumours infiltrating the skull base were treated at the Department of Otorhinolaryngology Head and Neck Surgery, University of Würzburg between 1987 and 1999.
  • Most of the tumours (n = 51) originated from the nose or paranasal sinuses, the epipharynx, the outer ear canal or the middle ear.
  • Seven tumours were malignant brain tumours infiltrating the bony structures of the skull base or originated from the cranial base itself.
  • The histological diagnosis was confirmed in 53 patients preoperatively and in seven patients during tumour resection.
  • RESULTS: A radical en bloc resection of the tumour was only possible in 26 out of 60 cases.
  • A surgical tumour reduction with postoperative radiation therapy was performed in seven patients as a palliative approach.
  • Eight patients underwent a combined radio- and chemotherapy according to the histological diagnosis.
  • Primary radiotherapy was the treatment of choice in eleven patients, where the tumours were located in the central area of the cranial base.
  • Palliative radiotherapy or solely medical pain control were applied to eight patients who presented either with distant metastases or an advanced tumour growth.
  • DISCUSSION: A statistical analysis of the results is not applicable due to the great variety of the disease concerning the histological diagnosis, the tumour size and the location as well as the small number of patients.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Squamous Cell. Esthesioneuroblastoma, Olfactory. Sarcoma. Skull Base Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Palliative Care. Postoperative Complications. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11555782.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Kataoka K, Sumii T, Asai T, Yamada Y, Kuroda R, Tsuzuki T, Kinoshita A, Taneda M: Successful treatment of large malignant tumor involving the skull base by radiosurgery combined with intraarterial chemotherapy and embolization. Minim Invasive Neurosurg; 2000 Mar;43(1):30-2
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of large malignant tumor involving the skull base by radiosurgery combined with intraarterial chemotherapy and embolization.
  • Stereotactic radiosurgery can be used to treat malignant tumors involving the skull base.
  • While it avoids extensive sacrifice of the normal structures surrounding the tumor, radiosurgery does not eradicate the tumor mass immediately.
  • We present a patient with a large hypervascular malignant tumor involving the skull base that resulted in intracranial hypertension.
  • He was successfully treated with stereotactic radiosurgery combined with intra-arterial chemotherapy and embolization of the arteries feeding the tumor.
  • We discuss radiosurgery, chemotherapy, embolization and other therapeutic modalities for treating large malignant tumors involving the skull base.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bone Neoplasms / surgery. Cisplatin / administration & dosage. Embolization, Therapeutic. Radiosurgery / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Infusions, Intra-Arterial. Magnetic Resonance Imaging. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10794563.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Daele JJ, Vander Poorten V, Rombaux P, Hamoir M: Cancer of the nasal vestibule, nasal cavity and paranasal sinuses. B-ENT; 2005;Suppl 1:87-94; quiz 95-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The usual clinical presentation of sinonasal tumours includes symptoms that are indistinguishable from inflammatory sinus disease, namely nasal airway obstruction, pain, and epistaxis.
  • Abnormal V1 and/or V2 sensations are a strong indication of the possibility of tumour.
  • Computed tomography is the most reliable and informative imaging tool for evaluating the cancers of the paranasal sinuses.
  • Magnetic resonance imaging is essential for tumour mapping because of the excellent tissue characterisation and the possibility of differentiating between neoplasms and retained secretions.
  • The response of sinonasal tract tumours to radiation therapy varies with the stage and histology of the tumour.
  • Patients with tumour involvement of the skull base, either in the infratemporal fossa or at the fovea ethmoidalis and cribriform plate, should be considered for craniofacial resection.
  • Management of these tumours requires a multimodal approach, involving surgery, radiation therapy and, increasingly in recent years, chemotherapy.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363270.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


12. Gil Z, Constantini S, Spektor S, Abergel A, Khafif A, Beni-Adani L, Leonor TL, DeRowe A, Fliss DM: Skull base approaches in the pediatric population. Head Neck; 2005 Aug;27(8):682-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull base approaches in the pediatric population.
  • BACKGROUND: This study aimed to examine the surgical, oncologic, and developmental results of infants and children undergoing extirpation of skull base tumors.
  • Eighteen cases (27%) involved malignant tumors, and 49 (73%) involved benign tumors.
  • The most common benign tumors were craniopharyngioma (n = 10) and juvenile nasopharyngeal angiofibroma (n = 8).
  • The most common malignant tumor was sarcoma (n = 5).
  • Thirty-six tumors (55%) involved the anterior skull base, and the rest involved the lateral (n = 24) and posterior (n = 7) skull base.
  • Subcranial, transfacial, and subfrontal approaches were used for extirpation of anterior skull base tumors.
  • Voluminous or malignant tumors were excised by use of combined approaches (subcranial-transfacial, subcranial-degloving, or pterional-degloving).
  • Twenty-two children underwent adjuvant therapy (chemotherapy, radiation, or both).
  • RESULTS: No severe postoperative complications (ie, meningitis, cerebrospinal fluid leak, tension pneumocephalus) and no perioperative mortality occurred.
  • Two and a half years later, 54 of the children (80%) are alive and well.
  • Five children, two with optic glioma and one each with squamous cell carcinoma, ependymoma, and germinoma, have died of their disease.
  • CONCLUSION: The extirpation of skull base tumors by use of conventional surgical techniques is feasible and safe among infants and children.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Skull Base / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Male. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 15957193.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Schultes G, Kärcher H, Gaggl A, Santler G: Computer assisted tumour resection of the skull base: case report. J Craniomaxillofac Surg; 2001 Dec;29(6):326-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer assisted tumour resection of the skull base: case report.
  • This case report demonstrates computer assisted resection of a skull base tumour after combined chemotherapy and irradiation, in a 40-year-old man with a squamous cell carcinoma of maxilla, zygoma, orbit and skull base.
  • The resection of the skull base was performed with computer assistance after conventional resection of the maxilla, midface, exenteration of the orbit and lymph node dissection.
  • Following combined chemotherapy and irradiation, the original, pretherapeutic tumour extent was marked on the new, presurgical CT scan enabling resection of the skull base with the use of a navigation microscope.
  • Thus planned resection from the presurgical CT could be transposed intraoperatively using the navigation system, and the skull base could be resected with precision.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Skull Base Neoplasms / surgery. Surgery, Computer-Assisted
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Transplantation. Chemotherapy, Adjuvant. Dose Fractionation. Follow-Up Studies. Humans. Lymph Node Excision. Male. Maxillary Neoplasms / surgery. Microsurgery. Muscle, Skeletal / transplantation. Orbit Evisceration. Orbital Neoplasms / surgery. Patient Care Planning. Radiotherapy, Adjuvant. Skin Transplantation. Skull Neoplasms / surgery. Surgical Flaps. Tomography, X-Ray Computed. Zygoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 European Association for Cranio-Maxillofacial Surgery.
  • (PMID = 11777349.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


14. Hof H, Welzel T, Debus J: Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie; 2006 Dec;29(12):572-4
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
  • BACKGROUND: Chordomas are rare tumors of the skull base and the spine.
  • Treatment is difficult since conventional radiotherapy or chemotherapy have only limited effects.
  • PATIENT AND METHODS: A patient with a sacral chordoma and pulmonary metastases received initial surgery and radiotherapy for a local recurrence.
  • As tumor biopsies revealed the expression of the EGF receptor an individual treatment approach with a combination of cetuximab and gefitinib was performed.
  • RESULTS: Under the treatment with cetuximab/gefitinib the local recurrence and the pulmonary metastases showed a partial response over the follow-up period of 9 months.
  • To date no treatment failure was observed.
  • CONCLUSIONS: The inhibition of the EGF pathway seems to be an effective measure in the treatment of a chordoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chordoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sacrum. Spinal Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Cetuximab. Humans. Male. Middle Aged. Quinazolines / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202828.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  •  go-up   go-down


15. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol Head Neck Surg; 2006 Jan;132(1):73-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study.
  • OBJECTIVE: To report postoperative mortality, complications, and outcomes in a subset of patients with the histologic diagnosis of malignant melanoma extracted from an existing database of a large cohort of patients accumulated from multiple institutions.
  • SETTING: Seventeen international tertiary referral centers performing craniofacial surgery for malignant skull base tumors.
  • PATIENTS: A total of 53 patients were identified from a database of 1307 patients who had craniofacial resection for malignant tumors at 17 institutions.
  • Of the 53 patients, 25 (47%) had had prior single modality or combined treatment, which included surgery in 22 (42%), radiation in 11 (21%), and chemotherapy in 2 (4%).
  • Adjuvant radiotherapy was given in 22 (42%), chemotherapy in 3 (6%), and vaccine or interferon therapy in 2 (4%).
  • Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) were determined using the Kaplan-Meier method.
  • With a median follow-up of 10 months (range, 1-159 months), the 3-year OS, DSS, and RFS rates were 28.2%, 29.7%, and 25.5%, respectively.
  • The extent of orbital involvement and adjuvant postoperative radiation therapy (PORT) were independent predictors of DSS and OS on multivariate analysis, whereas only PORT was an independent predictor of RFS.
  • CONCLUSIONS: Craniofacial resection in patients with malignant melanoma of the skull base has mortality (6%) and complication rates (26%) comparable to other malignant tumors of the skull base.
  • However, malignant melanoma is associated with a much poorer OS, DSS, and RFS.
  • These factors must be taken into account when considering craniofacial resection in a patient with malignant melanoma invading the skull base.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Facial Bones / surgery. Melanoma / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. International Cooperation. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415433.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Huang Q, Wu H, Wang Z, Zhang Z, Jia H: [Diagnosis and treatment of lateral skull base tumors in pediatric]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Aug;22(16):734-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of lateral skull base tumors in pediatric].
  • OBJECTIVE: To explore the diagnosis and treatment of lateral skull base tumors in children.
  • METHOD: The clinical data of 8 patients with lateral skull base tumors were reviewed in a retrospective study.
  • One had schwannoma of the trigeminal nerve, one had malignant melanoma, one had fibroma in temporal bone, one had chordoma, two had rhabdomyosarcoma, two had esthesioneuroblastoma.
  • Of 8 patients, one case was treated with chemotherapy.
  • The other 7 cases of benign or malignant tumors underwent surgery in different approaches.
  • Four patients had pre-and postoperative chemotherapy.
  • Three patients received postoperative chemotherapy.
  • One patient of chordoma died 5 months after surgery, the other 7 patients were alive at the time of analysis.
  • One patient developed hoarseness.
  • Two patients developed swallowing obstruction and healed 3-4 months after surgery.
  • CONCLUSION: Tumors in lateral skull base in children were rare, of which malignant tumors were more common compared to benign lesions.
  • CT and MRI are helpful in evaluating extent of disease and preoperative planning.
  • Surgery is the first choice of the treatment for lateral skull base tumors.
  • Radiation therapy and chemotherapy could be used for malignant tumors preoperatively and postoperatively.
  • Combined approach of temporal and infratemporal fossa is suitable for the surgery of those tumors involved temporal bone and middle or posterior cranial fossa as well as infratemporal fossa.
  • [MeSH-major] Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18975775.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Origitano TC, Petruzzelli GJ, Vandevender D, Emami B: Management of malignant tumors of the anterior and anterolateral skull base. Neurosurg Focus; 2002 May 15;12(5):e7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of malignant tumors of the anterior and anterolateral skull base.
  • OBJECT: Malignant tumors of the skull base represent a group of diverse and infrequent lesions.
  • Comprehensive oncological management requires a multidisciplinary team of neurological surgeons, otolaryngologists, radiation oncologists, plastic surgeons, and medical oncologists.
  • The authors describe an institutional experience in performing 54 combined anterior-anterolateral cranial base resections for malignant disease.
  • The influence on the natural history of the disease process is an ongoing study.
  • [MeSH-major] Case Management. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy / methods. Ethmoid Bone. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nasal Cavity. Neuronavigation. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery. Preoperative Care. Radiotherapy, Adjuvant. Radiotherapy, Conformal. Surgical Flaps. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119905.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A, Brabant G: Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary; 2002;5(4):261-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of tumors at the base of the skull comprises meningiomas, neurinomas, gliomas, metastatic carcinomas, chordomas, epidermoids, and pituitary adenomas.
  • About half of the pituitary adenomas are prolactinomas which are unique in a sense that medical therapy causes rapid tumor shrinkage and symptomatic improvement.
  • A massive invasively growing tumor was demonstrated on a cranial MRI.
  • A repeat prolactin (PRL) sample, which was assayed using serial dilutions, revealed a real PRL level of 89,700 ng/ml.
  • Dopamine agonist therapy was initiated under which PRL levels declined in parallel with tumor size.
  • Cranial MRI showed a large tumor at the base of the skull.
  • Based on a transnasal biopsy, the preliminary diagnosis was a poorly differentiated carcinoma for which emergency irradiation was performed.
  • Hydrocortisone was substituted and dopamine agonist therapy was started because of moderate hyperprolactinemia.
  • A repeat PRL sample assayed in serial dilution demonstrated an apparent rise in PRL with a maximum value of 6,460 ng/ml.
  • Under dopamine agonist therapy, PRL declined to normal values, tumor size decreased and cranial nerve palsies disappeared.
  • Serial dilutions of serum PRL samples is, therefore, mandatory in the diagnostic work-up of patients with large invasive tumors at the base of the skull.
  • This avoids unnecessary aggressive and dangerous treatment like surgery or radiotherapy in cases where pharmacological treatment may be the choice.
  • [MeSH-major] Pituitary Neoplasms / blood. Prolactin / blood. Prolactinoma / blood
  • [MeSH-minor] Adult. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. False Negative Reactions. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Pituitary Function Tests. Skull Base Neoplasms / blood. Skull Base Neoplasms / drug therapy. Skull Base Neoplasms / pathology. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Mar;44(3):305-9 [8729527.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):1789-93 [10843153.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2381-5 [9253304.001]
  • [Cites] N Engl J Med. 1985 Sep 12;313(11):656-9 [4022058.001]
  • [Cites] Arch Intern Med. 1993 Sep 27;153(18):2165, 2168 [8379808.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Mar;34(3):231-5 [2036731.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22 [10404830.001]
  • (PMID = 14558675.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down


19. Teschner M, Lenarz T, Stöver T: [The interesting case -- case number 61]. Laryngorhinootologie; 2004 Jul;83(7):470-2
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 58-year-old patient presented after having undergone radiation therapy, afterloading therapy and chemotherapy of a T4 nasopharynx carcinoma.
  • On the basis of the MRI findings, local tumour recurrence was suspected.
  • Neuroradiological imaging showed that the tumour extended into the area around the left skull base and also revealed an irregular formation located in the left temporal flap.
  • Therefore not only tumour resection (Fisch approach type C) but also a temporal craniotomy was indicated in order to determine the degree of intracerebral tumour extension.
  • The dura mater, which had been intact, was intraoperatively opened and revealed vital brain tissue, i. e. tumour infiltration had not reached the brain.
  • The presented case illustrates the rare differential diagnostic procedure carried out in a patient with radiogenic necrosis while taking into account the possibility of local tumour infiltration into the brain parenchyma.
  • [MeSH-major] Brachytherapy. Magnetic Resonance Imaging. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiation Injuries / diagnosis. Temporal Lobe / radiation effects
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm Invasiveness. Skull Base Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15257498.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Lee AW: Contribution of radiotherapy to function preservation and cancer outcome in primary treatment of nasopharyngeal carcinoma. World J Surg; 2003 Jul;27(7):838-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of radiotherapy to function preservation and cancer outcome in primary treatment of nasopharyngeal carcinoma.
  • Development of primary treatment for nasopharyngeal carcinoma is summarized and the contribution of radiotherapy (RT) is reviewed.
  • Accumulation of knowledge, together with technological advances, has led to significant improvement both for tumor control and organ preservation.
  • With contemporary RT, it is possible to achieve a 10-year disease-specific survival of 47% with a severe late complication rate of 5%.
  • The average local control rate is 80% for tumor confined within the nasopharynx, but only 50% for those associated with erosion of the base of the skull or cranial nerve involvement.
  • Successful locoregional control is important, not only because it is crucial for survival but also because it is associated with a lower incidence of distant failure (29% versus 41%).
  • Randomized trials exploring the value of additional chemotherapy are reviewed.
  • The significant improvement in 3-year overall survival achieved by the addition of concurrent and adjuvant chemotherapy (78% versus 47%) recently reported is encouraging, but remaining uncertainties are also discussed.
  • [MeSH-major] Brachytherapy / methods. Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging. Prognosis. Radiation Dosage. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 1957 Mar;66(1):5-40 [13411979.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):401-7 [7390921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):985-96 [9169804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):713-6 [6793542.001]
  • [Cites] Acta Radiol Oncol. 1980;19(6):433-8 [6263056.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):179-87 [10096252.001]
  • [Cites] Laryngoscope. 1988 Aug;98(8 Pt 1):881-3 [3135458.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):463-9 [8655368.001]
  • [Cites] Head Neck Surg. 1980 Sep-Oct;3(1):8-14 [7410101.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):943-9 [3607731.001]
  • [Cites] Laryngoscope. 1985 Mar;95(3):276-83 [3974378.001]
  • [Cites] Head Neck Surg. 1984 Dec;7(2):123-8 [6439690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):569-77 [7558945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):703-10 [9336153.001]
  • [Cites] Radiother Oncol. 1997 Apr;43(1):53-61 [9165137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):261-70 [1587745.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):629-34 [3549991.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):35-42 [9422555.001]
  • [Cites] Cancer. 1976 Jun;37(6):2605-12 [820419.001]
  • [Cites] Br J Radiol. 1993 Jun;66(786):528-36 [8330138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):301-5 [2921129.001]
  • [Cites] Head Neck. 1991 Jul-Aug;13(4):298-310 [1869431.001]
  • [Cites] Acta Radiol Oncol. 1985 Jul-Aug;24(4):315-20 [2994387.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):843-9 [2424585.001]
  • [Cites] Clin Radiol. 1982 Jan;33(1):95-9 [7067344.001]
  • [Cites] Acta Radiol Oncol. 1982;21(2):87-95 [6289617.001]
  • [Cites] AMA Arch Surg. 1954 Dec;69(6):841-8 [13206582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1789-93 [2412999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1005-12 [8985020.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1401-10 [3047335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 May;13(5):679-85 [3570892.001]
  • [Cites] Radiother Oncol. 1995 Jul;36(1):24-31 [8525022.001]
  • [Cites] Eur J Cancer. 1992;28A(11):1792-7 [1382499.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Aug;11(8):1455-9 [3926733.001]
  • [Cites] Br J Radiol. 1990 Jan;63(745):51-8 [2306588.001]
  • [Cites] Am J Surg. 1972 Oct;124(4):515-8 [4627679.001]
  • [Cites] J Otolaryngol. 1983 Jun;12(3):197-202 [6876247.001]
  • [Cites] Cancer. 1988 Mar 15;61(6):1117-24 [3342372.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Radiother Oncol. 1992 Feb;23 (2):79-93 [1546192.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1029-36 [7961008.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):261-71 [10030248.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1342-51 [2199621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):271-80 [1587746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):623-33 [2450858.001]
  • (PMID = 14509516.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


21. Nibu K, Sugasawa M, Asai M, Ichimura K, Mochiki M, Terahara A, Kawahara N, Asato H: Results of multimodality therapy for squamous cell carcinoma of maxillary sinus. Cancer; 2002 Mar 1;94(5):1476-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multimodality therapy for squamous cell carcinoma of maxillary sinus.
  • BACKGROUND: A wide variety of modalities, including surgery, radiation therapy, and chemotherapy, alone or in combination, have been used for the treatment of squamous cell carcinoma (SCC) of the maxillary sinus to obtain better local control and maintain functions.
  • However, there is still much controversy with regard to the optimum treatment.
  • The treatment consisted of 30-40 grays (Gy) of preoperative radiotherapy with concomitant intraarterial infusion of 5-fluorouracil and cisplatin followed by surgery and 30-40 Gy of postoperative radiotherapy, for tumors without skull base invasion.
  • For tumors invading the skull base, preoperative systemic chemotherapy with or without radiotherapy was performed, instead of intraarterial chemotherapy, then followed by skull base surgery.
  • The surgical procedures varied according to the extent of tumor.
  • Skull base surgery was performed in eight T4 patients.
  • CONCLUSIONS: Our multimodal treatment has provided favorable local control and survival outcome with good functional results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Retrospective Studies. Skull Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920504.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Hans FJ, Reinges MH, Nolte K, Reipke P, Krings T: Primary lymphoma of the skull base. Neuroradiology; 2005 Jul;47(7):539-42
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the skull base.
  • This case demonstrates the rare finding of a primary malignant lymphoma of the frontobasis and ethmoidal cells in a patient presenting with progressive loss of vision.
  • Computed tomography and MRI demonstrated a homogenously enhancing tumour with extensive bony destructions of the skull base.
  • After transsphenoidal biopsy, histology revealed a highly malignant primary B-cell lymphoma.
  • Tissue diagnosis is, therefore, crucial before a definitive therapy is instituted.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Magnetic Resonance Imaging. Paranasal Sinus Neoplasms / diagnosis. Skull Base Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Biopsy. Drug Therapy. Female. Humans. Immunotherapy. Middle Aged. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17(4):567-71 [8331227.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):395-9 [9031122.001]
  • [Cites] Neurosurgery. 1998 Sep;43(3):613-5; discussion 615-6 [9733317.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):50-8; discussion 58-60 [9218295.001]
  • [Cites] Blood. 1995 Oct 15;86(8):2873-5 [7579377.001]
  • [Cites] Surg Neurol. 1996 Sep;46(3):272-8; discussion 278-9 [8781598.001]
  • [Cites] Neurology. 1996 Feb;46(2):435-9 [8614508.001]
  • [Cites] Acta Neurochir (Wien). 2004 May;146(5):533-4 [15118895.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):393-6 [11515505.001]
  • [Cites] Clin Radiol. 2003 Aug;58(8):621-5 [12887955.001]
  • (PMID = 15940530.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Pallini R, Sabatino G, Doglietto F, Lauretti L, Fernandez E, Maira G: Clivus metastases: report of seven patients and literature review. Acta Neurochir (Wien); 2009 Apr;151(4):291-6; discussion 296

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tumours of the clivus are rare and metastases involving this area have been previously described only as single case reports or included in series with other skull base tumours.
  • METHOD: Clinical, radiological and follow-up data of patients who had undergone surgery for clivus tumours at our Institution between January 1995 and December 2007 were retrospectively collected.
  • FINDINGS: Of 46 patients who underwent surgery for clivus bone tumours, seven proved to harbour a metastasis.
  • This figure represents 0.18% and 0.42% respectively of intracranial and skull base tumours which were treated in our Institution in the study period.
  • The primary tumours associated were lung adenocarcinoma (n = 2), prostate carcinoma (n = 2), skin melanoma (n = 1), hepatocarcinoma (n = 1) and lung squamous cell carcinoma (n = 1).
  • All patients presented with a sixth nerve palsy as the symptom.
  • In spite of radiotherapy and chemotherapy, the mean survival was 12 months.
  • Including our series, the most common primary tumours were prostate cancer (26.4%), thyroid carcinoma (11.7%) and hepatocarcinoma (11.7%).
  • The metastatic lesion might be a late and single expression of the primary tumour.
  • The trans-sphenoidal approach is the ideal procedure to establish a histopathological diagnosis.
  • [MeSH-major] Carcinoma / secondary. Cranial Fossa, Posterior / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Abducens Nerve Diseases / etiology. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Prostatic Neoplasms / pathology. Skin Neoplasms / pathology. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19259614.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 30
  •  go-up   go-down


24. Rao G, Klimo P Jr, Jensen RL, MacDonald JD, Couldwell WT: Surgical strategies for recurrent craniofacial meningiomas. Neurosurgery; 2006 May;58(5):874-80; discussion 874-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Recurrent cranial base meningiomas are among the most difficult tumors to treat surgically.
  • Although they are histologically benign, these tumors often invade through the cranial base into the infratemporal and pterygopalatine fossae.
  • We reviewed our experience with these tumors to describe the natural history of these lesions as well as provide a possible treatment paradigm.
  • METHODS: Between 2000 and 2004, seven patients with meningiomas recurring through the cranial base into facial structures were treated at the University of Utah.
  • Five patients were treated with transcranial approaches only, and two were treated with a combination of transcranial and transfacial approaches.
  • The original site of tumor was the sphenoid wing in four patients, the middle fossa in two patients, and the left frontal region in one patient.
  • The average interval between the most recent tumor resection and recurrence into the face was 9.9 years.
  • All but one patient had adjunctive therapy (including either radiation or chemotherapy) before recurrence into the face.
  • CONCLUSION: Meningiomas that recur into facial structures present a unique treatment challenge.
  • These lesions have a high rate of recurrence once they have invaded through the cranial base.
  • [MeSH-major] Facial Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639321.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM: Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol; 2009 Jan;160(1):115-9
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Nelson's syndrome with temozolomide.
  • A 64-year-old woman was previously treated for Cushing's disease with trans-sphenoidal surgery, external beam radiotherapy and bilateral adrenalectomy.
  • Tumour spread through the skull base, occiput and left ear with persistent facial pain and left ear discharge; progression continued despite second gamma knife treatment.
  • Treatment with temozolomide resulted in a significant improvement in symptoms, a reduction of plasma ACTH to 389 pmol/l and regression of tumour on magnetic resonance imaging scan after four cycles of treatment.
  • We propose that temozolomide is an effective and well-tolerated therapeutic tool for the treatment of Nelson's syndrome and a useful addition to the range of therapies available to treat this condition.

  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984772.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


26. Muench E, Meinhardt J, Schaeffer M, Schneider UC, Czabanka M, Luecke T, Schmiedek P, Vajkoczy P: The use of the excimer laser-assisted anastomosis technique alleviates neuroanesthesia during cerebral high-flow revascularization. J Neurosurg Anesthesiol; 2007 Oct;19(4):273-9
MedlinePlus Health Information. consumer health - Brain Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with complex intracranial aneurysms or skull base tumors, parent vessel occlusion and flow replacement by high-flow bypass surgery is a demanding therapy, both for the neurosurgeon and the neuroanesthesiologist.
  • Twenty-nine patients with giant aneurysms (n=27) or skull base tumor (n=2) who were undergoing parent vessel occlusion and permanent flow replacement by high-flow bypass surgery using the ELANA technique were investigated retrospectively.
  • The records of the patients were analyzed for induction and maintenance of anesthesia, fluid therapy, transfusion requirements, hemodynamic parameters, and brain protective strategies.
  • Although we are not able to provide a sufficient body of cohort data to compare the neuroanesthesiologic management of patients undergoing the conventional anastomosis technique with management using the ELANA technique, in each of our reported cases the conventional anastomosis technique would have entailed a high probability of prolonged temporary occlusion that would, in turn, have warranted intensive brain-protective strategies.
  • [MeSH-major] Anastomosis, Surgical. Anesthesia, Intravenous. Cerebral Revascularization. Intracranial Aneurysm / surgery. Laser Therapy. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anesthetics, Intravenous / administration & dosage. Blood Pressure / drug effects. Cerebral Angiography. Data Collection. Female. Heart Rate / drug effects. Humans. Male. Middle Aged. Postoperative Care. Preoperative Care. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893581.001).
  • [ISSN] 0898-4921
  • [Journal-full-title] Journal of neurosurgical anesthesiology
  • [ISO-abbreviation] J Neurosurg Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous
  •  go-up   go-down


27. Wong LY, Lam LK, Fan YW, Yuen AP, Wei WI: Outcome analysis of patients with craniofacial resection: Hong Kong experience. ANZ J Surg; 2006 May;76(5):313-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to evaluate the clinical outcome of patients who underwent craniofacial resection for tumour in the anterior skull base at the University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong between January 1993 and June 2003.
  • Thirty-four patients had malignant tumour and five patients had benign pathology.
  • The tumour pathology was diversified.
  • Nineteen patients had no treatment before the surgery, and the remaining 20 patients had received surgery, radiotherapy or combined treatment before resection.
  • Patients were given postoperative irradiation and/or chemotherapy depending on the pathology of the tumour and the extent of the disease and clearance at the time of surgery.
  • The 5-year actuarial disease-free survival for patients with benign and malignant pathology was 100 and 77.6%, respectively.
  • For patients with malignant pathology, 5-year actuarial disease-free survival was 90% when the resection margin was negative at surgery.
  • CONCLUSION: Craniofacial resection was an appropriate surgical approach with acceptable morbidity in selected patients with tumour located at the anterior skull base.
  • Complete excision of malignant tumour could achieve 90% 5-year disease-free actuarial survival.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Facial Bones / surgery. Postoperative Complications. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Hong Kong. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768689.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Levy EI, Horowitz MB, Koebbe C, Jungreis CC: Target-specific multimodality endovascular management of carotid artery blow-out syndrome. Ear Nose Throat J; 2002 Feb;81(2):115-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Target-specific multimodality endovascular management of carotid artery blow-out syndrome.
  • We describe a novel multimodality endovascular approach to safely control hemorrhage from a carotid artery pseudoaneurysm and tumor vasculature associated with a squamous cell carcinoma.
  • This approach was used in the case of a 68-year-old man who had previously undergone a laryngectomy, chemotherapy, and brachytherapy and who subsequently experienced acute oropharyngeal bleeding.
  • Angiography detected a carotid artery pseudoaneurysm and significant tumor vascularity.
  • The tumor blush was treated with polyvinyl alcohol particles and both retrievable and nonretrievable coils.
  • Endovascular surgeons have become increasingly involved in the management of patients with carotid injuries and with neoplasms in and around the skull base.
  • Current endovascular technology provides a rapid target-specific approach to the treatment of carotid artery blow-out syndrome and has a greater potential to lower morbidity than does carotid sacrifice.
  • [MeSH-major] Aneurysm, False / therapy. Carotid Artery Diseases / therapy. Embolization, Therapeutic. Stents. Tongue Neoplasms / blood supply
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / complications. Hemoptysis / etiology. Hemoptysis / therapy. Humans. Male. Minimally Invasive Surgical Procedures. Syndrome

  • MedlinePlus Health Information. consumer health - Carotid Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11868472.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Prabhu SS, Demonte F: Treatment of skull base tumors. Curr Opin Oncol; 2003 May;15(3):209-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of skull base tumors.
  • The rich multidisciplinary environment in which skull base surgery has developed has allowed for significant progress in the field and has improved patient outcomes.
  • More precise and detailed anatomic dissection in the laboratories has provided surgeons with the benefit of undertaking the serious technical challenges encountered in the skull base.
  • Significant work has been done and continues to be developed in the field of adjuvant treatments including radiotherapy, chemotherapy, and hormonal therapy.
  • Using biologic end points and specific genetic targets in the tumors may further expand our management options in the future.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Skull Base
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Female. Glioma / mortality. Glioma / pathology. Glioma / therapy. Humans. Immunotherapy / methods. Male. Meningioma / mortality. Meningioma / pathology. Meningioma / therapy. Neoplasm Staging. Neurilemmoma / mortality. Neurilemmoma / pathology. Neurilemmoma / therapy. Neurosurgery / methods. Prognosis. Radiosurgery / methods. Radiotherapy, High-Energy / methods. Risk Assessment. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12778013.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


30. Demirci H, Marentette LJ, Nelson CC: The transglabellar/subcranial approach for surgical excision of periocular second tumors in retinoblastoma. Orbit; 2008;27(4):285-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transglabellar/subcranial approach for surgical excision of periocular second tumors in retinoblastoma.
  • PURPOSE: To evaluate the use of transglabellar/subcranial approach for surgical resection of periocular second non-ocular tumors in retinoblastoma patients.
  • METHODS: Seven retinoblastoma patients with periocular second tumor involving anterior skull base underwent surgical resection by transglabellar/subcranial approach in a single center.
  • RESULTS: The most common presenting symptom in retinoblastoma patients with periocular second tumor was difficulty in maintaining the prosthesis in three patients (43%), followed by epistaxis in one (14%), palpable orbital mass in one (14%), persistent periocular swelling in one (14%), and visual loss in one (14%) patient.
  • Periocular second tumors were leiomyosarcoma in three (43%) patients, osteosarcoma in three (43%), and sphenoid wing meningioma in one (14%) patient.
  • Surgical resection by the transglabellar/subcranial approach was the only treatment in one (14%) patient with sphenoid wing meningioma and was combined with chemotherapy in three (43%) patients, and with both external beam radiotherapy and chemotherapy in three (43%) patients.
  • Complications were minor, including cerebral spinal fluid (CSF) leak in one (14%) patient and CSF leak and subgaleal hematoma in one (14%) patient.
  • CONCLUSIONS: Retinoblastoma patients with periocular second tumors have a poor prognosis.
  • The transglabellar/subcranial approach can be used for surgical resection of periocular second tumor involving skull base with low morbidity.
  • [MeSH-major] Craniotomy / methods. Neoplasms, Second Primary / surgery. Ophthalmologic Surgical Procedures. Retinal Neoplasms / pathology. Retinoblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Eye Enucleation. Eyebrows. Female. Frontal Bone. Humans. Leiomyosarcoma / surgery. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Orbital Neoplasms / surgery. Osteosarcoma / surgery. Paranasal Sinus Neoplasms / surgery. Radiotherapy. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Retinoblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716966.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Sakuma I, Tomura N, Omachi K, Takahashi S, Watarai J, Sasajima T, Mizoi K: [A case of astrocytoma with extracranial extension after malignant transformation]. No To Shinkei; 2003 Feb;55(2):153-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of astrocytoma with extracranial extension after malignant transformation].
  • A case of astrocytoma with extracranial extension after malignant transformation is presented.
  • The initial magnetic resonance imaging (MRI) demonstrated a slightly hyperintense tumor on T 2-weighted images in the tip of the left temporal lobe, and no contrast enhancement on gadolinium-enhanced T 1-weighted images(Gd-T 1 WI).
  • On digital subtraction angiography, there was no tumor staining.
  • MRI revealed a remarkably growing tumor with ring-like enhancement on Gd-T 1 WI.
  • After surgery, chemotherapy and radiotherapy were performed.
  • The tumor invades the skull base and extended into the infratemporal fossa 25 months after surgery.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioblastoma / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12684996.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Jian JJ, Cheng SH, Tsai SY, Yen KC, Chu NM, Chan KY, Tan TD, Cheng JC, Lin YC, Leu SY, Hsieh CI, Tsou MH, Lin CY, Huang AT: Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys; 2002 Jun 1;53(2):344-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
  • PURPOSE: When the primary tumor of nasopharyngeal carcinoma (NPC) is treated at the base of skull and intracranium with conventional radiotherapy, the result is generally poor.
  • In this report, we investigated whether hyperfractionated radiotherapy (HFRT) and concomitant chemotherapy (CCT) could achieve better local control and survival in NPC patients with T3 and T4 lesions.
  • HFRT was administered at 1.2 Gy per fraction, two fractions per day, Monday-Friday for 62 fractions for a total dose of 74.4 Gy.
  • Concomitant chemotherapy consisting of cis-diamino-dichloroplatinum (CDDP) alone or CDDP and 5-fluorouracil was delivered simultaneously with radiotherapy during Weeks 1 and 6.
  • Adjuvant chemotherapy consisted of CDDP and 5-fluorouracil for 2 to 3 cycles and was given monthly beginning 1 month after completion of radiation.
  • RESULTS: With a median follow-up of 57 months (range: 28-94 months), the 3-year locoregional control rate was 93%, the disease-free survival rate was 71%, and the overall survival rate was 72%.
  • For T4 patients, the 3-year locoregional control rate was 91%, disease-free survival was 62%, and overall survival was 63%.
  • Most patients tolerated the combined modality treatments relatively well; 88% of patients completed their radiation treatment within 8 weeks.
  • The treatment-related toxicity was acceptable and reversible.
  • We would recommend using HFRT with CCT for advanced T-stage NPC if the three-dimensional conformal radiation planning shows a significant portion of the brainstem to be inside the treatment field.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mouth Mucosa. Neoplasm Metastasis. Neoplasm Staging. Patient Compliance. Stomatitis / etiology. Survival Rate. Weight Loss

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12023138.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Issing WJ, Taleban B, Tauber S: [Diagnosis and management of squamous cell carcinoma of the head and neck region with unknown primary. A survey of 167 patients]. Laryngorhinootologie; 2003 Sep;82(9):659-65
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Diagnose und Management von Plattenepithelkarzinomen mit unbekanntem Primärtumor im Kopf-Hals-Bereich.
  • BACKGROUND: Carcinoma of unknown primary is defined as histological diagnosis of metastasis without diagnosis of a primary tumor.
  • The incidence of CUP is stated in the literature between 3 % and 15 % of all patients with an malignant disease.
  • During the 10 year follow-up a primary tumor was found in 36 of the 167 initially diagnosed CUP-patients.
  • In over 90 % of these cases the tumor was localized in the head and neck region.
  • The origin of the tumor was most frequently the tonsilla palatina (n = 7).
  • Primary radiotherapy was the treatment of choice in 28 patients, 8 patients received combined radio-chemotherapy as primary treatment and 7 patients were treated with chemotherapy alone.
  • No treatment was performed in 6 patients.
  • RESULTS: By comparing the treatment methods there was a significant difference of patient survival in regard to the treatment.
  • Patients treated according to treatment-plan II, which includes an additional "diagnostic" tonsillectomy, is significantly higher than that of patients simply undergoing neck dissection and postoperative radiotherapy or primary radiotherapy alone.
  • Treatment of choice in patients with cervical CUP should be a surgical procedure including radical neck dissection and diagnostic bilateral tonsillectomy followed by postoperative radiation of the cervical lymph drainage.
  • DISCUSSION: Bilateral tonsillectomy is especially important and is correlated with a significant improvement of the survival rate in CUP patients.
  • Additional postoperative radiation of the pharynx from the base of the skull to the upper oesophagus should also be considered, in order to treat a possible--small--primary tumor in this region.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Retrospective Studies. Survival Analysis. Time Factors. Tonsillar Neoplasms / surgery. Tonsillectomy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14517763.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Dare AO, Datta RV, Loree TR, Hicks WL, Grand W: Sinonasal Non-Hodgkin's Lymphoma with Skull Base Involvement. Skull Base; 2001 May;11(2):129-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal Non-Hodgkin's Lymphoma with Skull Base Involvement.
  • Non-Hodgkin's lymphoma (NHL) is a rare tumor of the skull base.
  • As the incidence of primary central nervous system (CNS) lymphoma has increased, atypical presentations involving the skull or cranial base exclusively have been reported.
  • In immunocompetent patients with no previous history or predisposing factors, the diagnosis of primary NHL of the skull base may be delayed.
  • We present four cases of nasal and paranasal sinus NHL with both skull base and intracranial involvement in immunocompetent patients.
  • Clinicopathologic correlation suggests that cranial base and intracranial involvement with NHL represents advanced-stage primary sinonasal disease.
  • Surgical biopsy before definitive treatment is recommended.
  • Radiation therapy provides local control; adjuvant chemotherapy after primary radiation therapy may be required for recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol. 1981 Mar;7(1):23-31 [7214760.001]
  • [Cites] J Laryngol Otol. 1995 Aug;109(8):751-4 [7561500.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17(4):567-71 [8331227.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1634-42 [8635069.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Sep;31B(5):299-300 [8704645.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):395-9 [9031122.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Cancer J Sci Am. 1997 Sep-Oct;3(5):303-11 [9327155.001]
  • [Cites] Neurosurgery. 1998 Sep;43(3):613-5; discussion 615-6 [9733317.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4655-60 [9891536.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):222-5 [1590274.001]
  • [Cites] No Shinkei Geka. 1992 Jun;20(6):717-21 [1603282.001]
  • [Cites] Jpn J Clin Oncol. 1992 Apr;22(2):131-5 [1619780.001]
  • [Cites] Radiol Clin North Am. 1990 Jul;28(4):723-43 [2190267.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] J Comput Assist Tomogr. 1986 Nov-Dec;10(6):1003-5 [3465759.001]
  • [Cites] AJR Am J Roentgenol. 1987 Oct;149(4):785-91 [3498332.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Jun;112(6):654-8 [3516178.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):357-64 [3882644.001]
  • [Cites] Laryngoscope. 1983 Oct;93(10):1276-80 [6621224.001]
  • [Cites] Med J Aust. 1983 Oct 29;2(9):451-2 [6633410.001]
  • (PMID = 17167612.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1656785
  •  go-up   go-down


35. Pino Rivero V, Montero García C, Marcos García M, Trinidad Ruiz G, Pardo Romero G, González Palomino A, Alvarez Domínguez J, Blasco Huelva A: [Ethmoidal epidermoid carcinoma showing as cluster headache. Report of a case and literature review]. An Otorrinolaringol Ibero Am; 2004;31(5):477-83
Genetic Alliance. consumer health - Cluster headache.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinoma epidermoide etmoidal manifestándose con cluster headache. Caso clínico y revisión de la literatura.
  • Sino-nasal malignant tumours represent about 5%-6% in all ENT carcinomas and they use to be of later diagnosis, with high probability of local recurrence and invasiveness on structures like orbit and skull base.
  • The main treatment for ethmoidal squamous carcinomas is surgery and depending on staging can require radiotherapy and/or chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / pathology. Cluster Headache / complications. Ethmoid Bone / pathology. Paranasal Sinus Neoplasms / pathology

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15566268.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


36. Mishra A, El-Naggar AK, DeMonte F, Hanna EY: Endodermal sinus tumor of the paranasal sinuses. Head Neck; 2008 Apr;30(4):539-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endodermal sinus tumor of the paranasal sinuses.
  • BACKGROUND: We report a rare case of endodermal sinus tumor (EST) of the paranasal sinus in a 59-year-old man with a 6-week history of nasal obstruction.
  • The patient underwent 3 cycles of neoadjuvant chemotherapy consisting of ifosfamide, paclitaxel, and cisplatin, which resulted in significant regression of the tumor, but after the fourth cycle, the mass showed a slight increase in size.
  • The tumor was excised with clear margins through an anterior craniofacial approach to the skull base.
  • Histologic examination of the resected specimen showed extensive fibrosis with residual areas of viable tumor composed mainly of the poorly differentiated component with only residual microscopic foci of EST.
  • Adjuvant postoperative intensity-modulated radiation therapy was administered.
  • At 1-year follow-up, the patient was tumor free, with normal alpha-fetoprotein levels.
  • CONCLUSION: Because of the rarity of this entity, no standardized treatment protocol has been defined.
  • The involvement of the anterior skull base in our case necessitated a radical craniofacial resection, despite a partial response to chemotherapy.
  • [MeSH-major] Carcinoma / pathology. Endodermal Sinus Tumor / pathology. Neoplasms, Multiple Primary / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Humans. Ifosfamide / administration & dosage. Magnetic Resonance Imaging. Male. Middle Aged. Nasal Obstruction / etiology. Neoadjuvant Therapy. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Skull Base / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17902152.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


37. Kadashev BA, Kutin MA, Kalinin PL, Trunin IuK, Alekseev SN, Shkarubo AN: [Comparative assessment of the results of different surgical treatments in patients with pituitary adenomas infiltrating the cavernous sinus]. Zh Vopr Neirokhir Im N N Burdenko; 2004 Jul-Sep;(3):14-7; discussion 17
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative assessment of the results of different surgical treatments in patients with pituitary adenomas infiltrating the cavernous sinus].
  • Benign pituitary tumors or adenomas are highly common, occasionally inclined to infiltrate the adjacent structures, the cavernous sinus in particular.
  • Despite the fact that drug and radiation therapy are at present widely used treatments, surgical procedures remain highly topical.
  • Different modifications of two basic surgical methods (transcranial intradural and transsphenoidal) that fail to completely remove a tumor from the cavernous sinus in most cases are mostly frequently used as before.
  • Attempts to improve surgical procedures and introduction of current technologies have led to the emergence of an extradural method for tumor removal from the cavernous sinus and to the introduction of endoscopic monitoring during transsphenoidal operations.
  • A strategy of two-stage removal of pituitary tumors has simultaneously been developed.
  • The paper presents the results of surgical treatment of 297 patients with pituitary adenomas growing into the cavernous sinus, by using currently available procedures: transsphenoidal, transcranial intradural, and intra-extradural, and two-stage ones.
  • However, this method has a number of limitations in cases with tumor being grown into the cavernous sinus especially when there is a medial displacement of the intracavernous segment of the internal carotid artery.
  • Moreover, secondary tumor nodes that may be removed by transcranial intradural access are a contraindication to its use.
  • With this, attempts to remove a tumor from the cavernous sinus fail to ensure the desired completeness of removal from the cavernous sinus.
  • The application of an intra-extradural access is the most adequate procedure for tumor removal from the cavernous sinus.
  • The two-stage removal is the most adequate procedure in cases of simultaneously significant spread of a tumor intracranially and into the structures of the base of the skull.
  • [MeSH-major] Adenoma / surgery. Cavernous Sinus / pathology. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Vascular Neoplasms / surgery
  • [MeSH-minor] Activities of Daily Living. Adult. Endocrine System Diseases / etiology. Eye Diseases / etiology. Female. Humans. Male. Neoplasm Invasiveness. Postoperative Complications / etiology. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15490633.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


38. Palme CE, Irish JC, Gullane PJ, Katz MR, Devins GM, Bachar G: Quality of life analysis in patients with anterior skull base neoplasms. Head Neck; 2009 Oct;31(10):1326-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life analysis in patients with anterior skull base neoplasms.
  • BACKGROUND: Significant morbidity is associated with management of anterior skull base neoplasms.
  • QOL tools included the Functional Assessment of Cancer Therapy-Head & Neck, Centre for Epidemiologic Studies Depression Scale (CES-D), Atkinson Life Happiness Rating (ALHR), and Midface Dysfunction Scale (MDS).
  • RESULTS: Postoperative radiotherapy and chemotherapy was required in 16 and 2 patients, respectively.
  • CES-D > 16 and patients with recurrent disease correlated with a lower Total-FACT score.
  • Adjuvant radiotherapy correlated with a lower FACT-H&N score.
  • CONCLUSION: Anterior skull base neoplasms survivors have an overall acceptable QOL.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Quality of Life. Skull Base Neoplasms
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Health Status Indicators. Humans. Male. Middle Aged. Postoperative Period. Psychometrics. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley Periodicals, Inc.
  • (PMID = 19536852.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Narasimhan K, Kucuk O, Lin HS, Heilbrun LK, Carron M, Venkatramanamoorthy R, Mathog R: Sinonasal mucosal melanoma: a 13-year experience at a single institution. Skull Base; 2009 Jul;19(4):255-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventy-two percent presented with tumors extending to the skull base, frontal sinus, orbit, or cranium.
  • Tumor size ranged from 0.3 cm to 5.3 cm.
  • Most common surgical procedure was medial maxillectomy (12 patients).
  • Eight patients received chemotherapy, ten received radiotherapy and six received both.
  • Median recurrence-free survival (RFS) was 14.4 months, with a 1-year RFS rate of 55%.
  • Median overall survival (OS) was 19.3 months with a 1-year OS rate of 60% and a 2-year OS rate of 42%.
  • CONCLUSION: SNMM remains a disease that has eluded breakthroughs in treatment.
  • Further research in adjuvant therapies will be necessary to improve outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 1994 Mar;23(3):97-103 [8021847.001]
  • [Cites] Arch Pathol Lab Med. 1988 Jun;112(6):616-20 [3377660.001]
  • [Cites] Br J Radiol. 1991 Dec;64(768):1147-50 [1773274.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1993 Feb;18(1):34-6 [8448888.001]
  • (PMID = 20046593.001).
  • [ISSN] 1532-0065
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA022453
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2731469
  • [Keywords] NOTNLM ; Melanoma / nasal cavity / sinonasal mucosal melanoma / sinus
  •  go-up   go-down


40. Turowski B, Zanella FE: Interventional neuroradiology of the head and neck. Neuroimaging Clin N Am; 2003 Aug;13(3):619-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular interventions are important and helpful for treatment of various pathologies of the head and neck.
  • Interventional neuroradiology of the head and neck includes image-guided biopsies, vessel occlusion, and local chemotherapy.
  • Knowledge of anatomy, functional relationships between intra- and extracranial vessels, and pathology are the basis for therapeutic success.
  • The interventional neuroradiologist is responsible for appropriate selection of patients based on clinical information, indications, and risk assessment.
  • Neuroradiologic imaging, especially CT and MR imaging, and appropriate analysis of angiographic findings help ensure indication for treatment and plan an intervention.
  • Technical equipment, including an angiographic unit, catheters, needles, embolizing materials, and so forth, are important.
  • Indications for image-guided biopsies are preverterbal fluid-collections, spinal and paraspinal inflammations and abscesses, deep cervical malignancies, vertebral body, and skull base tumors.
  • Special care should be taken to preserve critical structures in this region, including spinal nerve roots, cervical plexus, main peripheral nerves, and vessels.
  • Indications for vessel occlusion are emergency situations to stop bleeding in vascular lesions (traumatic, malformation, or tumors) by reduction of pressure, preoperative reduction of blood flow to minimize the surgical risk, palliative occlusion of feeding vessels to produce tumor necrosis, or potential curative (or presurgical) occlusion of vascular malformations.
  • Examples of these interventions are: a hemangioma of the hard palate, a juvenile angiofibroma, a hemangiopericytoma, a malignant meningioma, a malignant fibrous histiocytoma, and a glomus tumor.
  • Effective treatment of vascular malformations, such as AV fistulas or angiomas, needs exact occlusion of the fistula or the angiomatous nidus, which is demonstrated in the case of an AV angioma of the base of the tongue.
  • Chemotherapy with local intra-arterial cisplatin combined with intravenous administration of sodium thiosulfate as antidote is indicated as an adjuvant modality in a multimodal regimen of oropharyngeal squamous cell carcinoma or as palliative treatment of recurrent and otherwise untreatable malignant tumors of the head and neck.
  • Examples are a carcinoma of the alveolar ridge, a squamous cell carcinoma of the floor of the mouth, and a nasopharyngeal lymphoepithelioma.
  • Palliative treatment of a bleeding oropharyngeal cancer is another example of interventional treatment.
  • Selective treatment, either occluding or pharmacologic, may be preoperative, palliative, or curative.
  • The objective is reduction of surgical risk, improvement of quality of life, or curative therapy of a lesion.
  • Thus, the interventional treatment should not be associated with morbidity or mortality.
  • Major complications, such as cerebral stroke, blindness, or cranial nerve palsies, can result from application of inappropriate techniques or poor evaluation of angiographic findings and should be avoided in the majority of cases.
  • Based on neuroradiologic experience, most of those risks are predictable.
  • The benefits, risks, and expected damages of neuroradiologic interventions must be balanced during the informed consent procedure with the patient.
  • Continuing education is a firm basis to push the limits of interventions and expand benefits without increasing risk for the patient.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / therapy. Neuroradiography. Radiology, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631695.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


41. Roever AC, Rickes S, Flath B, Possinger K: [Ptosis and ophthalmoplegia as predominant signs of multiple myeloma]. Dtsch Med Wochenschr; 2004 Feb 27;129(9):434-6
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ptosis und Ophthalmoplegie als Leitsymptome eines multiplen Myeloms.
  • Five month later she presented with a pathological fracture of the clavicle.
  • INVESTIGATIONS: A mass in the clivus extending into the left sphenoid sinus as well as multiple osteolytic lesions in the skull were shown by cranial MRI.
  • DIAGNOSIS, TREATMENT AND COURSE: The biopsy taken from the mass at the sphenoid sinus demonstrated plasmacytoma.
  • The diagnosis of multiple myeloma was based on the histological evidence of plasmacytoma and the occurrence of multiple lytic bone lesions although no infiltration of bone marrow and none of the specific laboratory findings were present.
  • The patient underwent local radiotherapy with 30 Gy followed by systemic chemotherapy.
  • The symptoms regressed completely under this therapy.
  • CONCLUSION: Various cranial nerve syndromes such as the superior orbital fissure syndrome are most often caused by tumors at the skull base.
  • Knowledge of the histological entity is essential for the correct diagnosis and the appropriate therapy because rare tumors like multiple myeloma may also cause such syndromes.
  • [MeSH-major] Blepharoptosis / etiology. Multiple Myeloma / diagnosis. Ophthalmoplegia / etiology. Skull Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Paranasal Sinus Neoplasms / complications. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / therapy. Plasmacytoma / diagnosis. Plasmacytoma / pathology. Plasmacytoma / surgery. Radiotherapy, Adjuvant. Sphenoid Sinus / pathology. Sternum / pathology. Sternum / surgery. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / pathology. Thoracic Neoplasms / surgery. Tolosa-Hunt Syndrome / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Ptosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14970915.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Noël G, Dessard-Diana B, Vignot S, Mazeron JJ: [Treatment of nasopharyngeal cancer: literature review]. Cancer Radiother; 2002 Apr;6(2):59-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of nasopharyngeal cancer: literature review].
  • [Transliterated title] Les traitements des cancers du nasopharynx: revue de la littérature.
  • The conventional radiotherapy and the associated treatments improved the prognostic of nasopharyngeal cancer.
  • A better selection of the patients who must have a more aggressive treatment also probably contributed to this improvement.
  • It results from it that the improvement of local control rate necessarily does not result in a better control of the disease.
  • The patients with a locally advanced tumor, with or not an invasion of the base of the skull and/or neurological symptoms, must have an aggressive locally treatment.
  • This probably includes the increase in dose delivered to the tumor via a more conformational radiotherapy, a brachytherapy, radiotherapy in stereotaxic conditions or other techniques.
  • Dose within the tumor must be at least 70 Gy and the prophylactic nodal dose, at least 50 Gy.
  • Association with chemotherapy allowed, on the other hand, an improvement of the prognostic locally advanced cancers.
  • Neoadjuvant or adjuvant chemotherapy was largely used to attempt to limit the risks of systemic dissemination, but an improvement of results was not clearly demonstrated.
  • An improvement of the rates of survival and control of the disease, on the other hand, was observed in a certain number of studies with the chemoradiotherapy.
  • In the event of locoregional relapse, an aggressive attitude can allow the control of the disease in the absence of systemic dissemination.
  • Salvage treatments are, however, disappointing for when distant relapse occurs which suggests a difference in chemosensitivity between primary tumor and metastasis.
  • [MeSH-major] Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12035485.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 186
  •  go-up   go-down


43. Witt TC, Lo SS, Timmerman RD: Successful treatment of a skull base malignant rhabdoid tumor with surgery, chemotherapy and gamma Knife-based stereotactic radiosurgery in a young child. Stereotact Funct Neurosurg; 2007;85(6):310-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a skull base malignant rhabdoid tumor with surgery, chemotherapy and gamma Knife-based stereotactic radiosurgery in a young child.
  • Most childhood rhabdoid tumors occur in the kidney or central nervous system but they can occur in other sites and they usually run an aggressive clinical course.
  • We report a case of an 8-month-old boy with a right temporal bone rhabdoid tumor treated with surgery, chemotherapy and Gamma Knife-based stereotactic radiosurgery.
  • There were no obvious endocrine deficits or growth abnormalities at last follow-up.
  • Gamma Knife-based stereotactic radiosurgery may have a role in the management of very young children with skull base tumors.
  • [MeSH-major] Radiosurgery. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / surgery. Skull Base Neoplasms / drug therapy. Skull Base Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Infant. Magnetic Resonance Imaging. Male. Stereotaxic Techniques / instrumentation

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • [ErratumIn] Stereotact Funct Neurosurg. 2010;88(6):389
  • (PMID = 17709987.001).
  • [ISSN] 1423-0372
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. Chang DW, Langstein HN, Gupta A, De Monte F, Do KA, Wang X, Robb G: Reconstructive management of cranial base defects after tumor ablation. Plast Reconstr Surg; 2001 May;107(6):1346-55; discussion 1356-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstructive management of cranial base defects after tumor ablation.
  • Successful reconstruction after cranial base tumor ablation is paramount in preventing potentially life-threatening complications.
  • The purpose of this study was to evaluate experiences of cranial base reconstruction and to identify reconstructive management principles that may assist in achieving successful cranial base reconstruction.
  • All cranial base reconstructions performed by the Department of Plastic Surgery at the University of Texas M. D.
  • Analyses were performed to assess the impact of location of defect, type of reconstruction, type of dural repair, and history of preoperative radiation and chemotherapy on rates of complications, and patient survival.
  • The 77 patients who underwent cranial base reconstruction after tumor ablation during the study period had a mean age of 52 years (6 to 84 years).
  • Squamous cell carcinoma, the most common histopathologic type, was present in 24 patients (31 percent), and 35 patients (45 percent) presented with recurrent disease.
  • The type of reconstruction, location of defect, type of dural repair, and history of preoperative radiation and chemotherapy had no significant association with the incidence of complications.
  • Neither the type of reconstruction nor the location of defect showed a significant effect on patient survival.
  • In this experience, local flaps, such as pericranial or temporalis muscle flaps, are good choices for reconstruction of smaller anterior or lateral cranial base defects.
  • For defects that require larger amounts of soft tissue, free flaps are appropriate.
  • With proper patient selection, successful cranial base reconstruction can be performed with either local or free flaps with a low incidence of complications.
  • [MeSH-major] Reconstructive Surgical Procedures. Skull Base Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Child. Humans. Middle Aged. Neoplasm Recurrence, Local / surgery. Postoperative Complications. Retrospective Studies. Sarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11335798.001).
  • [ISSN] 0032-1052
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Shah JP, Gil Z: Current concepts in management of oral cancer--surgery. Oral Oncol; 2009 Apr-May;45(4-5):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral cancer is the sixth most common cancer worldwide, with a high prevalence in South Asia.
  • Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers.
  • The factors that affect choice of treatment are related to the tumor and the patient.
  • Tumors that approach or involve the mandible require specific understanding of the mechanism of bone involvement.
  • The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity.
  • Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy.
  • The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches employing chemotherapy and radiotherapy either sequentially or concurrently.
  • On the other hand, for early staged tumors of the larynx and pharynx, transoral laser microsurgery has become an effective means of local control of these lesions.
  • Advances in skull base surgery have significantly improved the survivorship of patients with malignant tumors of the paranasal sinuses approaching or involving the skull base.
  • Surgery thus remains the mainstay of management of a majority of neoplasms arising in the head and neck area.
  • Similarly, the role of the surgeon is essential throughout the life history of a patient with a malignant neoplasm in the head and neck area, from initial diagnosis through definitive treatment, post-treatment surveillance, management of complications, rehabilitation of the sequelae of treatment, and finally for palliation of symptoms.
  • [MeSH-major] Mouth Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Protocols. Bone Neoplasms / surgery. Combined Modality Therapy. Head and Neck Neoplasms / surgery. Humans. Patient Selection. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps. Treatment Outcome


46. Farias TP, Dias FL, Lima RA, Kligerman J, de Sá GM, Barbosa MM, Gonçalves FB Jr: Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg; 2003 Jul;129(7):794-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Nasopharyngeal cancer (NPC) is a distinct form of cancer of the upper respiratory or digestive tract in which the epidemiologic features, origin, histopathologic types, treatment, and prognosis are different from those associated with other malignant neoplasms of this anatomical area.
  • Recent publications have demonstrated the advantage of aggressive multimodality treatment for advanced NPC.
  • OBJECTIVES: To evaluate the results of standardized treatment of NPC during 11 years and to identify pertinent factors for clinical outcome.
  • METHODS: Between January 1, 1989, and December 31, 2000, 173 patients with newly diagnosed NPC were treated at Instituto Nacional de Cancer.
  • Documented data of the initial presenting symptoms, head and neck examination, radiotherapy protocols, chemotherapy regimens, and surgical technique were analyzed.
  • To determine important prognostic factors, we correlated survival rates with age, clinical stage, tumor extent, histopathological type, and therapeutic approach.
  • RESULTS: Most patients (88.5%) had locoregional advanced disease, mostly (53.4%) of the nonkeratinizing subtype.
  • Gross extension of the primary tumor involving the facial bones and skull base was observed in 39.3% and 20.8%, respectively.
  • Just under 75% of patients were treated with radiotherapy (median dose, 6600 cGy), and 25.4% underwent concomitant chemoradiotherapy with adjuvant chemotherapy (cisplatin plus 5-fluorouracil) (median dose, 6800 cGy).
  • The 5-year disease-specific survival for the 173 patients was 32.3%.
  • The disease-specific survival for the radiotherapy group was 22.5%, compared with 61.4% for the chemoradiotherapy plus adjuvant chemotherapy group (P =.004).
  • Factors associated with adverse outcomes were age older than 40 years at treatment (P =.001), advanced TNM stage (P =.002), skull base invasion (P =.004), and facial bone invasion (P<.001).
  • CONCLUSIONS: Compared with radiotherapy alone, concomitant chemoradiotherapy with adjuvant chemotherapy improved the treatment outcome of patients with NPC treated in our institution.
  • Advanced age, local extension, and stage of the disease adversely affected the prognosis in our patients.
  • [MeSH-major] Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Brachytherapy. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874084.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Liu SH, Chang JT, Ng SH, Chan SC, Yen TC: False positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. Br J Radiol; 2004 Mar;77(915):257-60
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient.
  • Nasopharyngeal carcinoma (NPC) is treated by radiotherapy with or without chemotherapy.
  • It is not uncommon to find the residual/recurrent lesion in the skull base area.
  • For patients who had received radiotherapy, it is difficult to differentiate the skull base tumour from post-treatment change in the CT or MRI. (18)F-2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) provides an alternative diagnostic choice in this situation for head and neck cancer including NPC especially when there is inconclusive CT/MRI finding.
  • This report of an NPC patient who received radiotherapy 18 months previously, describes the misdiagnosis of tumour recurrence at the skull base found in both MRI and FDG PET scan.
  • Histopathological studies showed osteoradionecrosis of the debrided tissue and follow-up PET showed complete regression of the skull base lesion.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Nasopharyngeal Neoplasms / radionuclide imaging. Osteoradionecrosis / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15020372.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 18
  •  go-up   go-down


48. Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven Vv, Nikkhah G, Frommhold H, Volk B, Schumacher M, Lücking C, Zentner J, Ostertag C: The brain tumor board: lessons to be learned from an interdisciplinary conference. Onkologie; 2005 Jan;28(1):22-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The brain tumor board: lessons to be learned from an interdisciplinary conference.
  • BACKGROUND: The aim of this study is to analyze the work of the interdisciplinary Brain Tumor Board (BTB) which was established at Freiburg University Hospital in 1998.
  • RESULTS: In 79% of the patients, the diagnosis was based on histological findings or a typical radiological appearance of a lesion, or both.
  • This group was composed of 4 subgroups: 28% benign skull base tumors (19% meningiomas, 4% pituitary adenomas, 3% acoustic schwannomas, 2% others), 24% primary brain tumors of glial origin (8% glioblastomas, 12% gliomas other than glioblastomas, 5% oligoastrocytomas or oligodendrogliomas), 19% brain metastases, and 8% other brain or skull base tumors.
  • The recommendations given by the BTB included: 23% further diagnostic procedures (11% non-invasive examinations, 12% stereotactic biopsies), 57% active antitumoral therapy (22% resection, 17% fractionated radiotherapy, 13% radiosurgery, 5% chemotherapy, <1% embolization), 20% no treatment (14% watchful waiting, 6% supportive care).
  • CONCLUSION: Interdisciplinary care seems to be particularly necessary in patients with benign skull base tumors, gliomas and brain metastases.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials Data Monitoring Committees / statistics & numerical data. Decision Support Systems, Clinical / statistics & numerical data. Outcome Assessment (Health Care). Patient Care Team / statistics & numerical data. Quality Assurance, Health Care / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15616378.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


49. Kin S, Wanibuchi M, Minamida Y, Yamaki T, Tanabe S, Houkin K: [A case of sinonasal carcinoma with intracranial invasion treated by a multidisciplinary team]. No Shinkei Geka; 2003 Jun;31(6):677-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 66-year-old male with diffuse infiltration of neoplasm from the paranasal sinuses to the orbit and left cerebral hemisphere, associated with prominent edema.
  • Neuroimaging showed marked invasion of a neoplasm from the left paranasal sinuses into the intracranial space and to the frontal skull.
  • Radical removal of the neoplasm and left orbital content with reconstruction of the anterior skull base using musculocutaneous flap was carried out by a multidisciplinary team.
  • Postoperatively the patient received radiation and chemotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Small Cell / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Neoplasm Invasiveness. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12833878.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Brennan B: Nasopharyngeal carcinoma. Orphanet J Rare Dis; 2006;1:23
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.
  • Although rare, NPC accounts for about one third of childhood nasopharyngeal neoplasms.
  • 2) non-keratinizing carcinoma;.
  • The tumor can extend within or out of the nasopharynx to the other lateral wall and/or posterosuperiorly to the base of the skull or the palate, nasal cavity or oropharynx.
  • Symptoms related to the primary tumor include trismus, pain, otitis media, nasal regurgitation due to paresis of the soft palate, hearing loss and cranial nerve palsies.
  • Larger growths may produce nasal obstruction or bleeding and a "nasal twang".
  • The recommended treatment schedule consists of three courses of neoadjuvant chemotherapy, irradiation, and adjuvant interferon (IFN)-beta therapy.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Child. Child, Preschool. Global Health. Humans. Incidence. Infant. Infant, Newborn. Neoplasm Staging / methods. Prognosis. Radiotherapy / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Mar;41(3):1128-33 [638955.001]
  • [Cites] IARC Sci Publ. 1978;(20):115-29 [730188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):487-91 [7390929.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):360-6 [7459824.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):163-9 [7053813.001]
  • [Cites] Med Pediatr Oncol. 1982;10(3):243-50 [7087893.001]
  • [Cites] Int J Cancer. 1983 Aug 15;32(2):171-6 [6874140.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1984 Sep-Oct;93(5 Pt 1):477-82 [6093669.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):956-61 [3940655.001]
  • [Cites] J Laryngol Otol. 1987 Dec;101(12):1248-53 [3323380.001]
  • [Cites] Int J Cancer. 1988 Aug 15;42(2):176-81 [2841245.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(2):143-52 [3153224.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4003-6 [8033130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jun;3(4):305-10 [8061578.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1357-60 [8067705.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1188-91 [10096545.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):850-7 [15641027.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):1083-9 [15999363.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5452-5 [10554016.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2351-5 [10811107.001]
  • [Cites] J Pediatr. 1974 Jan;84(1):96-100 [12119964.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Arch Surg. 1967 Feb;94(2):214-7 [6016269.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Laryngoscope. 1972 May;82(5):807-16 [4337403.001]
  • [Cites] Nat New Biol. 1973 Aug 22;244(138):245-7 [4353684.001]
  • [Cites] J Pediatr. 1975 Feb;86(2):254-8 [1111694.001]
  • [Cites] Int J Cancer. 1975 Apr 15;15(4):651-7 [1173575.001]
  • (PMID = 16800883.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  • [Other-IDs] NLM/ PMC1559589
  • [General-notes] NLM/ Original DateCompleted: 20070719
  •  go-up   go-down


51. Guntinas-Lichius O, Kreppel MP, Stuetzer H, Semrau R, Eckel HE, Mueller RP: Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol; 2007 Mar;33(2):222-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients.
  • AIMS: To assess the single and multimodal treatment results and prognostic factors for sinonasal carcinoma.
  • METHODS: Overall survival (OS), disease-specific survival (DSS), local control (LC), and disease-free survival (DFS) in 229 patients with sinonasal carcinoma treated from 1967 to 2003 were calculated.
  • RESULTS: 32% of the patients were operated only, 47% underwent multimodal therapy, and 20% were treated without operation.
  • Prognostic for DSS were M status (p<0.001), UICC stage (p<0.001), T classification (p=0.001), N status (p=0.002), intracranial tumor infiltration (p=0.008), infiltration of the pterygopalatine fossa (p=0.02), infiltration of the skull base (p=0.021), infiltration of the orbita (p=0.041), and the type of therapy (p<0.001): The 5-year DSS rate was 63% for patients operated only, 56% for all operated patients, 46% for patients undergoing surgery and radiotherapy, but only 21% for patients treated with radiotherapy+/-chemotherapy.
  • Multivariate analysis revealed that T classification (p=0.042), N classification (p=0.035), M classification (p=0.007), UICC stage (p=0.038), and type of therapy (p=0.038) were independent prognostic factors for DSS.
  • Stage III/IV carcinomas still have a poor prognosis, but multimodal treatment seems to favor the outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Nose Neoplasms / therapy. Otorhinolaryngologic Surgical Procedures / methods. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Germany / epidemiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate / trends. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127030.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. House JW, Kutz JW Jr: Bone-anchored hearing aids: incidence and management of postoperative complications. Otol Neurotol; 2007 Feb;28(2):213-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of patients had unilateral profound sensorineural hearing loss after removal of an acoustic neuroma or skull base tumor (59.1%) with the next most common etiology of deafness secondary to sudden sensorineural hearing loss (16.1%).
  • Skin overgrowth was a late complication, occurring an average of 12 months after the initial procedure.
  • [MeSH-major] Hearing Aids. Hearing Loss, Sensorineural. Neuroma, Acoustic / complications. Neuroma, Acoustic / surgery. Postoperative Complications / epidemiology. Postoperative Complications / surgery. Skull Base Neoplasms / complications. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged, 80 and over. Female. Humans. Incidence. Male. Mastoid / surgery. Middle Aged. Prostheses and Implants. Retrospective Studies. Surgical Wound Infection / drug therapy. Surgical Wound Infection / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Hearing Aids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255890.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • MAIN OUTCOME MEASURES: Oncologic outcomes, including disease recurrence and survival.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The most common site of tumor origin was the nasal cavity (52%), followed by the ethmoid sinuses (28%).
  • Approximately 10% of the tumors had an intracranial epicenter, most commonly around the olfactory groove.
  • Tumors extended to or invaded the skull base in 20% and 11% of the patients, respectively.
  • An intracranial epicenter (P < .001) and extension to (P = .001) or invasion of (P < .001) the skull base were significantly more common in patients treated with CEA than in those treated with EEA.
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • Approximately two-thirds (63%) of the patients treated with EEA had a lower (T1-2) disease stage, while 95% of patients treated with CEA had a higher (T3-4) disease stage (P < .001).
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Other, less common tumors included adenoid cystic carcinoma (7%), neuroendocrine carcinoma (4%), and sinonasal undifferentiated carcinoma (2%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • With a mean follow-up of 37 months, 18 patients (15%) experienced local recurrence, with a local disease control of 85%.
  • Regional and distant failure occurred as the first sign of disease recurrence in 6% and 5% of patients, respectively.
  • The 5- and 10-year disease-specific survival rates were 87% and 80%, respectively.
  • Disease recurrence and survival did not differ significantly between the EEA group and the CEA group.
  • CONCLUSIONS: To the best of our knowledge, this is the largest US series to date of patients with malignant tumors of the sinonasal tract treated with endoscopic resection.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Samprón N, Arrazola M, Urculo E: [Skull-base plasmacytoma with craniocervical instability]. Neurocirugia (Astur); 2009 Oct;20(5):478-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skull-base plasmacytoma with craniocervical instability].
  • [Transliterated title] Plasmocitoma de base craneal con inestabilidad cráneo-cervical.
  • INTRODUCTION: Cranio-cervical instability is, in some cases, the main surgical concern in posterior skull base tumors.
  • We report on a case in which a solitary plasmacytoma of the skull base presented with cranio-cervical instability.
  • CASE REPORT: A 66 year-old woman was diagnosed of a cranial base solitary plasmacytoma and treated with radio and chemotherapy with complete remission.
  • After receiving that treatment, she presented with tetraparesis and a cranio-cervical instability was diagnosed.
  • She was operated on, under cranial traction, of posterior occipito-cervical instrumentation with C1 to C2 transarticular Magerl screws.
  • CONCLUSIONS: Transarticular screws at the C1 to C2 level of the cervical spine may provide rigid fixation in posterior cranio-cervical instrumentation for osteolytic lesions, but there is a risk of injury to the vertebral artery, specially when some variations in the surgical anatomy exist.
  • [MeSH-major] Atlanto-Occipital Joint / pathology. Joint Instability / etiology. Occipital Bone / pathology. Osteolysis / etiology. Plasmacytoma / complications. Quadriplegia / etiology. Skull Base Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cervical Atlas / surgery. Combined Modality Therapy. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Internal Fixators. Magnetic Resonance Imaging. Neuroaspergillosis / drug therapy. Neuroaspergillosis / etiology. Postoperative Complications / drug therapy. Pulmonary Aspergillosis / drug therapy. Pulmonary Aspergillosis / etiology. Remission Induction. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19830373.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down


55. Adelstein DJ: The role of chemotherapy for skull base carcinomas and sarcomas. Neurosurg Clin N Am; 2000 Oct;11(4):681-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy for skull base carcinomas and sarcomas.
  • The rarity of most primary skull base carcinomas and sarcomas has prevented a careful examination of the role of chemotherapy in these diseases.
  • For advanced nasopharyngeal cancer, however, convincing data have now been generated supporting the role of systemic chemotherapy in conjunction with definitive locoregional treatment.
  • Chemotherapy also seems to have a role in the management of other squamous cell head and neck cancers, and its use concurrently with radiation may be appropriate when extension to the base of the skull is identified.
  • The role of chemotherapy in the management of the other skull base neoplasms remains less well established.
  • Existing evidence is little more than anecdotal, and the use of systemic chemotherapy should generally be restricted to the palliative treatment setting.
  • The ultimate role of this intervention in the aggressive sinonasal undifferentiated carcinomas and primary neuroendocrine carcinomas is unknown, but for these diseases, chemotherapy is a reasonable addition to locoregional treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Sarcoma / drug therapy. Skull Base Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11082178.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 94
  •  go-up   go-down


56. Gil Z, Patel SG, Singh B, Cantu G, Fliss DM, Kowalski LP, Kraus DH, Snyderman C, Shah JP, International Collaborative Study Group: Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study. Cancer; 2007 Sep 1;110(5):1033-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study.
  • BACKGROUND: Single-institutional studies lack sufficient power to assess the role of surgery and radiotherapy in the management of sarcomas involving the anterior skull base.
  • For this study, an international collaborative study group analyzed a large cohort of patients who underwent surgery for the treatment of skull base tumors.
  • METHODS: A subset of 146 patients who had a histologic diagnosis of skull base sarcoma (SBS) formed the basis of this report.
  • Most patients were aged > or =21 years (77%) and had stage IV disease (56%).
  • Adjuvant radiotherapy was received by 35% of patients, and chemotherapy was received by 10% of patients.
  • Treatment-related complications were reported in 27% of patients, and postoperative mortality was reported in 1.4% of patients.
  • With a median follow-up of 34 months, the 5-year overall, disease-specific, and recurrence-free survival rates were 62%, 64%, and 57%, respectively.
  • Tumor grade and adjuvant radiotherapy were not significant predictors of survival.
  • Prior radiotherapy, intraorbital extension, positive margins, and postoperative complications were significant predictors of reduced disease-specific survival on univariate analysis.
  • The presence of positive/close margins, however, was the only independent predictor of poor overall, recurrence-free, and disease-specific survival on multivariate analysis (relative risk, 2.4; P = .006).
  • The 5-year disease-specific survival rate was 77%, 43%, and 36% for patients with negative, close, and positive margins, respectively.
  • Patients with positive margins have a high risk for tumor recurrence independent of tumor grade.
  • [MeSH-major] Sarcoma / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Postoperative Complications. Prognosis. Skull Base / drug effects. Skull Base / radiation effects. Skull Base / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2007 Sep 1;110(5):939-40 [17634947.001]
  • (PMID = 17614334.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Lee KL, Terris MK: Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology; 2003 Aug;62(2):351
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma.
  • The relative contraindication of hormonal therapy for patients with prostate cancer and a history of meningioma has not been widely emphasized.
  • Using immunohistochemistry to determine the presence of hormone receptors in meningioma specimens proved potentially valuable in 2 patients with biochemical recurrence after prostatectomy who were being considered for androgen deprivation therapy.
  • These cases also highlight the need for caution against assuming that skull-based intracranial growths in patients receiving hormonal therapy for prostate cancer are metastatic lesions rather than hormonally induced primary tumors.
  • [MeSH-major] Gonadotropin-Releasing Hormone / adverse effects. Gonadotropin-Releasing Hormone / agonists. Meningeal Neoplasms / chemically induced. Meningioma / chemically induced
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / chemically induced. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / chemically induced. Prostatectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893358.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


58. Kumagai T, Takeda N, Fukase S, Koshu H, Inoue A, Ibuchi Y, Yoneoka Y: Intra-arterial Chemotherapy for Malignant Tumors of Head and Neck Region Using Three Types of Modified Injection Method. Interv Neuroradiol; 2003 May 15;9(Suppl 1):113-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial Chemotherapy for Malignant Tumors of Head and Neck Region Using Three Types of Modified Injection Method.
  • SUMMARY: Relatively higher infusion rate in the intra-arterial chemotherapy (IA chemotherapy) could induce the higher concentration and the more sufficient distribution of chemotherapeutic agents on tumors.
  • To get the relatively higher infusion rate in IA chemotherapy, we used three types of injection method: high-flow injection, high-dose injection with detoxification and flowcontrolled injection method for the treatment of malignant brain tumors, skull base tumors and head and neck tumors.
  • Between January 1997 and October 2001, twenty-seven patients (mean age 61 y.o.) with supratentorial glioblastoma (4 cases), supratentorial anaplastic astrocytoma (1), CNS lymphoma (2), matastatic skull base tumors (3), and neck tumors (15 squamous cell carcinoma, 1 malignant melanoma and 1 neuroblastoma) received our three types of IA chemotherapy.
  • Conventional radiation therapy and/or surgical removal were performed in some of these patients.
  • Fifteen (55.6%) and 6 (22.2%) of 27 patients achieved complete response (CR) and partial response (PR) respectively after initial treatment [CR+PR: 21 (77.8%)].
  • The median post treatment survival was 12 months.
  • Our modified IA chemotherapy has provided favorable clinical and radiological results without technical difficulties and serious complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Oct;213(1):135-40 [10540653.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Cancer. 2000 May 15;88(10):2350-6 [10820358.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):63-70 [11131988.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):79-86 [8455066.001]
  • [Cites] Radiology. 1993 Aug;188(2):347-50 [8327676.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71 [9226312.001]
  • [Cites] Biol Pharm Bull. 1999 Apr;22(4):428-31 [10328568.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):235-46 [10359143.001]
  • [Cites] J Neurooncol. 1999 Mar;42(1):73-7 [10360481.001]
  • [Cites] Microcirculation. 2000 Dec;7(6 Pt 1):405-10 [11142337.001]
  • [Cites] Radiology. 2001 Mar;218(3):724-32 [11230646.001]
  • [Cites] Am J Clin Oncol. 2001 Jun;24(3):241-6 [11404493.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1079-85, viii [11728933.001]
  • [Cites] Head Neck. 2002 Jan;24(1):68-77 [11774405.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1476-82 [11920504.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1989 Mar;41(3):293-300 [2471758.001]
  • [Cites] J Neurosurg. 1991 May;74(5):763-72 [1849555.001]
  • (PMID = 20591239.001).
  • [ISSN] 1591-0199
  • [Journal-full-title] Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
  • [ISO-abbreviation] Interv Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3553465
  •  go-up   go-down


59. Orzan F, Terreni MR, Longoni M, Boari N, Mortini P, Doglioni C, Riva P: Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas. Oncol Rep; 2007 Jul;18(1):249-52
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
  • Chordomas are rare neoplasms arising along the axial skeleton.
  • Up to now, the most suitable therapeutic approach is based on a combination of surgical excision and radiotherapy.
  • Chemotherapy in not applied due to its reported low efficacy.
  • We analyzed 14 chordoma samples for the expression of the Imatinib mesylate targets by means of RT-PCR and immunohistochemistry and found that PDGFR alpha and PDGFR beta are in some cases expressed in neoplastic cells, while the stromal counterpart of the same tumor shows the above receptors.
  • Our study provides new insights into the specific localization of Imatinib mesylate targets in skull base chordomas that could be taken into account for the setting up of a pharmacological treatment for this tumor.
  • [MeSH-major] Chordoma / metabolism. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism. Skull Base Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Benzamides. Female. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / metabolism. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


60. Oskouian RJ Jr, Jane JA Sr, Dumont AS, Sheehan JM, Laurent JJ, Levine PA: Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience. Neurosurg Focus; 2002 May 15;12(5):e4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience.
  • Esthesioneuroblastoma is a rare and malignant upper nasal cavity neoplasm involving the anterior skull base.
  • Treatment includes surgery, radiotherapy, chemotherapy, or a combination.
  • The ideal treatment modality has yet to be determined.
  • Resection risks damaging these critical structures, and radiotherapeutic techniques, similar to those applied for paranasal sinus tumors, may damage these vital structures and result in late sequelae such as blindness and cortical necrosis.
  • Management strategies for this neoplasm lack uniformity, and there is no universally accepted staging system.
  • In this paper the authors discuss the clinical presentation, radiological and pathological features, and treatment of this rare, malignant skull base neoplasm, as well as review the literature.
  • They also present their results and treatment regimen, which includes preoperative radio- and chemotherapy or 1) craniofacial resection if the lesion has a significant intracerebral component, or 2) frontal sinus resection if little intracranial extension exists.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Cavity. Nose Neoplasms
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119902.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 71
  •  go-up   go-down


61. Pacheco-Ojeda L: Malignant carotid body tumors: report of three cases. Ann Otol Rhinol Laryngol; 2001 Jan;110(1):36-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant carotid body tumors: report of three cases.
  • The aim of the current report was to describe 3 cases of malignant carotid body tumor (CBT) and to review the literature.
  • Three malignant cases were found.
  • He was treated with chemotherapy and interferon, but died with disseminated disease 2 years later.
  • The second case was in a 56-year-old woman who had a 5-cm, fixed, hard mass in the upper aspect of the neck and a paralysis of the left vocal cord.
  • This lesion was completely resected, and a shunt and reconstruction with a saphenous vein graft were performed.
  • Pathology revealed a malignant chemodectoma with invasion to 2 of the 5 lymph nodes removed.
  • Radiotherapy (50 Gy) was given after the operation.
  • She is well and free of disease 68 months after the resection.
  • On computed tomography, the tumor extended to the infratemporal fossa with no bone involvement.
  • The lesion was embolized with a 40% reduction in vascularity.
  • At surgical exploration, the tumor involved the sternocleidomastoid muscle and the lymph nodes at levels II and III, and the internal carotid artery could not be dissected free at the skull base, so only a partial resection was performed.
  • Locoregional control is usually obtained with complete primary tumor resection and lymphadenectomy and eventual radiotherapy.
  • Current multidisciplinary treatments have been unsuccessful in controlling disseminated disease.
  • [MeSH-major] Carotid Body Tumor. Paraganglioma, Extra-Adrenal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11201806.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


62. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional spread of nonneurogenic tumors to the skull base via the facial nerve.
  • OBJECTIVE: This study examined the clinical and pathologic features of regional spread of nonneurogenic neoplastic disease to the intratemporal segments of the facial nerve.
  • PATIENTS: Six patients with neoplastic disease of nonneurogenic origin involving segments of the facial nerve within the temporal bone.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • MAIN OUTCOME MEASURES: Histopathology, site of primary tumor, intratemporal location of regional spread along the facial nerve, degree of facial paralysis, and presence of residual disease.
  • Perineural spread was histologically found in all cases of malignant disease.
  • In addition, one case of benign pleomorphic adenoma of the parotid gland that circumferentially involved an intratemporal segment of the facial nerve was reported.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.
  • CONCLUSIONS: The facial nerve provides a route for the spread of neoplastic disease into the temporal bone, and perineural invasion is an important mechanism of invasion and motility of malignant disease.
  • Nonneurogenic intratemporal tumors of the facial nerve are a rare but significant cause of facial paralysis.
  • [MeSH-major] Carcinoma / pathology. Cranial Nerve Neoplasms / pathology. Facial Nerve / pathology. Parotid Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Child. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Radiopharmaceuticals. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


63. Isaka T, Maruno M, Suzuki T, Sato M, Yoshimine T: Skull metastases from atypical pulmonary carcinoid tumor in a 19-year-old man. Neurol Med Chir (Tokyo); 2006 Dec;46(12):609-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull metastases from atypical pulmonary carcinoid tumor in a 19-year-old man.
  • A 19-year-old man presented with a rare skull metastasis from atypical pulmonary carcinoid tumor (APCT) manifesting as headache, diplopia, and cough.
  • Head magnetic resonance imaging showed a skull base tumor extending from the posterior clinoid process to the clivus, and calvarial tumors in the right temporal and occipital bones.
  • Chest and abdominal computed tomography showed a round tumor, 4 cm in diameter, in the lower lobe of the right lung and multiple small tumors in the liver.
  • Surgery for the calvarial tumor in the right temporal bone was performed on June 27, 2003.
  • The histological diagnosis was skull metastasis of neuroendocrine tumor.
  • Gamma knife radiosurgery was performed for the residual skull metastases.
  • Partial resection of the right lower lobe was performed for the lung tumor on August 22, 2003.
  • The histological diagnosis was atypical carcinoid tumor.
  • Subsequent adjuvant systematic chemotherapy was performed.
  • The patient died of progression of the tumors in the lung and liver on April 19, 2004.
  • We must consider APCT in the differential diagnosis of pulmonary tumors in adolescents, and perform follow-up observation or treatment, including surgery, if APCT is suspected.
  • [MeSH-major] Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skull Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185889.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Shikama N, Oguchi M, Sasaki S, Shinoda A, Nishikawa A, Arakawa K, Koiwai K, Mochizuki K, Yamada A, Watanabe T, Kadoya M: Evaluation of central nervous system involvement in nasal lymphomas. Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jun;61(7):342-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To clarify the usefulness of evaluating central nervous system (CNS) involvement in patients with nasal lymphomas at the initial staging procedure, and of CNS prophylaxis for patients with clinical stage I/II.
  • The staging procedure included mainly computed tomography (CT), ultrasonography, gallium scintigraphy, upper gastrointestinal study, magnetic resonance (MR) imaging, and bone marrow biopsy.
  • Forty-two patients received radiotherapy, and 25 patients received chemotherapy.
  • RESULTS: Four patients demonstrated CNS involvement at the staging procedure.
  • MR imaging demonstrated the tumor had directly infiltrated the skull base in 3 patients, but CT demonstrated CNS infiltration in only one patient.
  • No patient with stage I/II developed CNS relapse.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Lymphoma, Non-Hodgkin / pathology. Nose Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496414.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Yonekawa Y: [On the occasion of my retirement as head of the Neurochirurgische Universitätsklinik Zürich--changing aspects of treatment modality in modern neurosurgery and of neuroscience research. Presentation of our experience and historical backgrounds]. Brain Nerve; 2008 May;60(5):538-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [On the occasion of my retirement as head of the Neurochirurgische Universitätsklinik Zürich--changing aspects of treatment modality in modern neurosurgery and of neuroscience research. Presentation of our experience and historical backgrounds].
  • May 2007, the changing aspects of neurosurgery in diseases dealt with and in their treatments during the last 70 years (from the foundation of the department by Prof. Krayenbuehl in 1937 successed by Prof. Yaşargil and later on by myself.) were presented.
  • Number of surgical procedures were 1,000 times per year during the interval and the busiest era was that of Prof. Krayenbühl, in which it amounted to as much as 1,500 at the maximum.
  • Although "new" technique such as Chymopapain injection or endoscopic methods have been applied, microsurgical lumbar disc surgery remains as the gold standard.
  • Traditionally, carotid endarterectomy belonged to vascular surgeons in our hospital, but the tendency of conversion from conventional carotid endarterectomy to endovascular PTA and/or stenting seemed to be marked, while microvascular revascularization procedure represented by extracranial intracranial EC-IC bypass remained constant (around 20/year) in various occasion (277 times on 203 cases: atherosclerosis 93, Moyamoya angiopathy (MMA) 47, aneurysm 57 and skull base tumour 6, during the last 13 years], in spite of negative results of EC-IC bypass international cooperative study for stroke prevention in 1985.
  • Glioma surgery especially glioblastoma surgery the most frequent surgery in our department around 170 / year contributed to improvement of both life expectancy and quality of life by development of therapy modalities (irradiation microsurgery and chemotherapy).
  • Recent life expectancy of cases with primary glioblastoma amounted to 25.8 ms on the average by combination of treatments; microsurgical gross total removal + irradiation + temodal and thalidomide.
  • This was 8.5 ms and 14 ms respectively at the time of Prof. Krayenbühl 1960 (surgical removal plus irradiation) and of Prof. Yaşargil 1970 (microsurgical removal plus irradiation) and these results being those on cases of primary and secondary glioblastoma together.
  • Acoustic neurinoma (just less than 20/year) is one of benign brain tumours whose treatment has changed remarkably.
  • Shunting procedure for hydrocephalus malresorptivus (after subarachnoid hemorrhage and/or idiopathic) were around 100/year.
  • [MeSH-minor] Brain Neoplasms / surgery. Cerebral Revascularization / methods. Cerebral Revascularization / trends. Humans. Hydrocephalus / surgery. Intracranial Aneurysm / surgery. Intracranial Arteriovenous Malformations / surgery. Switzerland. Universities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516976.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 33
  •  go-up   go-down


66. Constantinidis J, Steinhart H, Koch M, Buchfelder M, Schaenzer A, Weidenbecher M, Iro H: Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg; 2004 May;130(5):567-74
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Olfactory neuroblastoma constitutes a rare and, in clinical terms, biologically variable tumor of the nasal cavity, paranasal sinuses, and the base of the skull and presents a challenge to a modern multidisciplinary therapy.
  • Generally acknowledged prognostic factors and a standard therapy fail to exist.
  • Fifty-two percent were thus classified as low-grade and 48% as high-grade tumors.
  • Surgical therapy was performed on 23 patients (88.5%), surgery being the exclusive form of therapy (monotherapy) in 5 of these patients.
  • Combined therapy was carried out in 18 cases (surgery, radiotherapy, chemotherapy).
  • The disease-specific 10- and 15-year survival determined according to Kaplan-Meier is 76.2%.
  • Fifteen-year survival amounts to 86.7% for smaller tumors (Kadish A/B) and 63.6% for advanced tumors (Kadish C).
  • Seven (26.9%) of the overall group of treated patients developed a recurrence.
  • Salvage therapy was successful in 60% (3 of 5 patients).
  • Fifteen-year survival following salvage therapy amounts to 60%.
  • Patients with high-grade tumors exhibit a significantly reduced 10-year survival (40%) compared to patients with low-grade tumors (100%).
  • CONCLUSIONS: The therapy of olfactory neuroblastoma calls for an interdisciplinary multimodal therapeutic strategy, particularly in the case of advanced tumors.
  • Tumor staging and histopathologic grading according to Hyams are important factors for survival and prognosis.
  • Aggressive salvage therapy can lead to a distinct improvement of long-term survival.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity / pathology. Nose Neoplasms / pathology. Nose Neoplasms / therapy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15138422.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Ware ML, Larson DA, Sneed PK, Wara WW, McDermott MW: Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma. Neurosurgery; 2004 Jan;54(1):55-63; discussion 63-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma.
  • OBJECTIVE: Recurrent atypical and malignant meningiomas are difficult to treat successfully.
  • Chemotherapy to date has been unsuccessful, and radiosurgery is limited to smaller tumors.
  • Reoperation alone provides limited tumor control and limited prolonged survival.
  • The addition of brachytherapy at the time of operation is an option.
  • Here, we report the results of our series of patients with recurrent malignant meningioma treated with resection and brachytherapy with permanent low-dose (125)I.
  • METHODS: The charts of patients in our database with recurrent atypical and malignant meningiomas treated by surgical resection and permanent (125)I brachytherapy at the University of California, San Francisco, between 1988 and 2002 were selected for this study.
  • Calculations of disease-free survival and overall survival curves were made by the Kaplan-Meier actuarial method.
  • Univariate analysis between Kaplan-Meier curves was based on the log-rank statistic, with a significance level set at a value of P </= 0.05.
  • RESULTS: Seventeen patients had recurrent malignant meningioma, and four had recurrent atypical meningioma.
  • The median number of sources implanted after surgical resection was 30 (range, 4-112 sources), with a median total activity of 20 mCi (range, 3.3-85.9 mCi).
  • The median time to progression after brachytherapy was 11.6 months for patients with malignant meningioma and 10.4 months for the combined group.
  • There was a trend toward longer disease-free survival time in patients after gross total resection versus subtotal resection and in patients with tumors located at the convexity and parasagittally versus at the cranial base.
  • The median overall survival after diagnosis was 9.4 years for patients with atypical meningioma, 6.6 years for those with malignant meningioma, and 8.0 years for all patients combined.
  • Survival from the time of resection and implantation of (125)I was 1.6 years for patients with atypical meningioma, 2.4 years for patients with malignant meningioma, and 2.4 years for the combined group.
  • CONCLUSION: The options for patients with recurrent atypical or malignant meningiomas are limited.
  • Our results suggest that for tumors not suitable for radiosurgery, resection followed by permanent brachytherapy should be considered as a potential salvage treatment.
  • However, this approach results in a relatively high complication rate in these heavily treated patients and requires meticulous surgical technique and medical therapies to assist with wound healing after surgery.
  • [MeSH-major] Brachytherapy. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14683541.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Muto E, Shioyama Y, Nakamura K, Ohga' S, Nomoto S, Toba T, Yoshitake T, Soeda H, Terashima H, Honda H: Adult rhabdomyosarcoma in the nasal and paranasal sinuses showing complete local response to a combination of chemotherapy and radiotherapy using 3D-CRT and IMRT. Fukuoka Igaku Zasshi; 2005 Oct;96(10):363-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult rhabdomyosarcoma in the nasal and paranasal sinuses showing complete local response to a combination of chemotherapy and radiotherapy using 3D-CRT and IMRT.
  • She was referred to our hospital with a reduced ability to smell and impaired bilateral vision, narrowing of the visual field, and left facial pain.
  • Computed tomography (CT) revealed a large tumor in the nasal and left paranasal sinuses invading the left orbital cavity and anterior skull base, and lymph node swellings in the submental and left accessory nerve areas.
  • A biopsy specimen from the nasal tumor was diagnosed histologically as a rhabdomyosarcoma, alveolar type.
  • Radiotherapy with a total dose of 60 Gy was carried out to control the primary disease.
  • Combined with radiotherapy, chemotherapy was also performed for the treatment of lymph-node metastases and distant diseases.
  • After the treatment was completed, the primary tumor and lymph-node metastases disappeared completely; there was no sign of re-growth during the follow-up period.
  • Chemoradiotherapy may be an effective treatment also for inoperable adult rhabdomyosarcoma in the head and neck region.
  • Furthermore, the 3D-CRT and IMRT techniques are both useful methods of radiotherapy for this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Conformal / methods. Radiotherapy, Intensity-Modulated / methods. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408493.001).
  • [ISSN] 0016-254X
  • [Journal-full-title] Fukuoka igaku zasshi = Hukuoka acta medica
  • [ISO-abbreviation] Fukuoka Igaku Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  •  go-up   go-down


69. Zanation AM, Ferlito A, Rinaldo A, Gore MR, Lund VJ, McKinney KA, Suárez C, Takes RP, Devaiah AK: When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol; 2010 Nov;267(11):1667-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esthesioneuroblastoma is an uncommon tumor that presents in the sinonasal cavity and anterior skull base.
  • This presents the treating physician with the difficult decision as to how and when to treat the neck in this disease.
  • The aims of this study were to provide a comprehensive review of the incidence of N+ disease at presentation, make recommendations about the optimal treatment strategy of patients with N+ disease, explain the role of elective neck treatment in patients with N0 disease, and comment on treatment of patients with late cervical metastases that require salvage therapy, using the literature review of the incidence and treatment of neck disease in patients with esthesioneuroblastoma.
  • This review revealed an approximately 5-8% incidence of cervical nodal metastasis at the time of presentation.
  • Combined modality therapy with surgery and radiotherapy is recommended to treat the N+ neck at the time of diagnosis and later.
  • Chemotherapy may have a role combined with radiation treatment, but there are little data to support this.
  • The results indicate that the management of the neck in esthesioneuroblastoma continues to be a significant challenge in the treatment algorithm of these complex patients.

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Sep;22(6):550-8 [10941155.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Head Neck. 2011 Oct;33(10):1520-9 [20737485.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):443-9 [20421144.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2010;72(2):113-8 [20453548.001]
  • [Cites] Rhinol Suppl. 2010;(22):1-143 [20502772.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Oct;135(10):1030-4 [19841344.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2009 Sep;266(9):1333-52 [19597837.001]
  • [Cites] Laryngoscope. 2009 Jul;119(7):1412-6 [19444891.001]
  • [Cites] Oral Oncol. 2009 Apr-May;45(4-5):402-8 [19375379.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Sep;29(8):1561-3 [18499797.001]
  • [Cites] J Surg Oncol. 2008 Jun 15;97(8):658-64 [18493946.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):215-21 [11936917.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Head Neck. 2003 Jul;25(7):529-34 [12808655.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1935-8 [14603051.001]
  • [Cites] Head Neck. 1992 Nov-Dec;14(6):477-82 [1468921.001]
  • [Cites] J Laryngol Otol. 1998 Jul;112(7):628-33 [9775291.001]
  • [Cites] Acta Neurochir (Wien). 2005 Jun;147(6):595-601; discussion 601-2 [15806328.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8 [16490869.001]
  • (PMID = 20706843.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC005360-07; United States / NIDCD NIH HHS / DC / T32 DC005360; United States / NIDCD NIH HHS / DC / T32 DC005360-07
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Other-IDs] NLM/ NIHMS255289; NLM/ PMC3005584
  •  go-up   go-down


70. Rutz HP, Weber DC, Goitein G, Ares C, Bolsi A, Lomax AJ, Pedroni E, Coray A, Hug EB, Timmermann B: Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents: initial experience at paul scherrer institute. Int J Radiat Oncol Biol Phys; 2008 May 1;71(1):220-5
Genetic Alliance. consumer health - Chordoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents: initial experience at paul scherrer institute.
  • PURPOSE: To evaluate postoperative spot-scanning proton radiation therapy (PT) and intensity-modulated PT (IMPT) for chordoma and chondrosarcoma in pediatric patients.
  • Tumor sites were in the brain (one case), skull base (five cases), cervical (three cases), and lumbar spine (one case).
  • In seven children, resection was incomplete, leaving residual tumor behind (range, 2.3-46.3 mL).
  • Total dose was 74.0 cobalt Gray equivalents (CGE) for chordoma, and 63.2-68.0 CGE for chondrosarcoma (median, 66.0), depending on histopathological grading and whether the patient had concurrent chemotherapy.
  • RESULTS: Median follow-up time was 36 months (range, 8-77 months).
  • Radiation treatment was well tolerated.
  • Longer follow-up time and larger cohort are needed to more fully assess tumor control, adverse events, as well as functional and cosmetic outcome.
  • [MeSH-major] Chondrosarcoma / radiotherapy. Chordoma / radiotherapy. Protons / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Child. Female. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / surgery. Humans. Male. Neoplasm Recurrence, Local / radiotherapy. Postoperative Period. Radiation Injuries / complications. Radiotherapy, Intensity-Modulated. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068310.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


71. Gadwal SR, Fanburg-Smith JC, Gannon FH, Thompson LD: Primary chondrosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 14 cases with a review of the literature. Cancer; 2000 May 1;88(9):2181-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chondrosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 14 cases with a review of the literature.
  • The literature contains several single cases and small series; however, to the authors' knowledge, there has been no previous comprehensive larger study to evaluate the clinicopathologic aspects of these tumors.
  • METHODS: Fourteen cases of chondrosarcoma of the head and neck from patients age 18 years or younger, diagnosed between 1970 and 1997, were retrieved from the Otorhinolaryngic-Head & Neck Tumor Registry of the Armed Forces Institute of Pathology.
  • No secondary sarcomas (radiation-induced or arising in association with Maffucci syndrome or Ollier disease) were included.
  • Patient symptoms (nasal stuffiness or discharge, sinusitis, headaches, or a mass lesion) were related to tumor location and were present for an average of 7.2 months.
  • The tumors most frequently involved the maxillary sinus (n=4), followed by the mandible (n=3), nasal cavity (n=2), and neck (n=2), with 1 each of the nasopharynx, orbit, and base of the skull.
  • The tumors ranged in size from 2.0 to 15.0 cm (mean, 3.1 cm).
  • All tumors were invasive and malignant as determined by radiology and/or histology.
  • The tumors were Grade 1 (n=9), Grade 2 (n=1), or Grade 3 (mesenchymal, n=2; dedifferentiated n=2).
  • All patients were treated by surgery, followed by radiation (n=5) and/or chemotherapy (n=2).
  • Follow-up was available for 11 patients; all were alive (at a mean of 14.8 years), with only a single patient demonstrating evidence of residual/ recurrent tumor (at 16.6 years).
  • Despite the invasive and high grade nature of some of these tumors, there is an excellent long term prognosis for patients in this age group with tumors in these locations.
  • [MeSH-major] Chondrosarcoma / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Headache / diagnosis. Humans. Male. Mandibular Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Nasal Obstruction / diagnosis. Neoplasm Invasiveness. Nose Neoplasms / pathology. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhinitis / diagnosis. Sinusitis / diagnosis

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813732.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 41
  •  go-up   go-down


72. Kraus DH, Gonen M, Mener D, Brown AE, Bilsky MH, Shah JP: A standardized regimen of antibiotics prevents infectious complications in skull base surgery. Laryngoscope; 2005 Aug;115(8):1347-57
Hazardous Substances Data Bank. METRONIDAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A standardized regimen of antibiotics prevents infectious complications in skull base surgery.
  • OBJECTIVES/HYPOTHESIS: Craniofacial surgery has been associated with a significant improvement in disease outcome for patients with skull base neoplasms.
  • This regimen was compared with a group of historic controls in which antibiotics were administered on an ad hoc basis.
  • The specific objectives/hypothesis were to determine 1) the incidence and severity of infection in a group of patients treated with a nonstandardized antibiotic regimen undergoing craniofacial resection, and 2) whether the use of a prospectively designed, three-drug, broad spectrum antibiotic is associated with a reduced incidence and severity of infections.
  • STUDY DESIGN: A single-arm, prospective antibiotic regimen consisting of ceftazidime, flagyl (metronidazole), and vancomycin (CMV) was compared with a historic control of patients treated with nonstandard antibiotic therapy (nonCMV), all of whom underwent craniofacial resection.
  • Demographics, prior therapy, anatomic site of origin and extent of disease, pathology, standard surgical data, and postoperative therapy were detailed.
  • Disease outcome, including incidence of postoperative mortality, was maintained for each patient.
  • Major medical comorbidities were present in 53 (25%) patients, and 96 (46%) had prior therapy.
  • The standardized antibiotic therapy (CMV) was used in 90 patients, and the nonstandardized antibiotics (nonCMV) were used in 107 patients.
  • Free flap reconstruction was the sole surgical factor associated with a marked reduction in complications.
  • Patients who received nonCMV antibiotic therapy faced a risk of infection that was 2.5 times higher than those who received CMV.
  • Hospital stay in days and operative mortality were both adversely affected by the use of nonCMV antibiotic therapy.
  • CONCLUSIONS: The data supports the hypothesis that the use of a three-drug, broad spectrum antibiotic regimen in skull base surgery reduces the incidence of infectious complications and appears to reduce operative mortality.
  • [MeSH-major] Antibiotic Prophylaxis. Drug Therapy, Combination / standards. Drug Therapy, Combination / therapeutic use. Skull Base Neoplasms / surgery. Surgical Wound Infection / prevention & control
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Case-Control Studies. Ceftazidime / therapeutic use. Female. Humans. Logistic Models. Male. Metronidazole / therapeutic use. Middle Aged. Neoplasm Staging. Neurosurgical Procedures / adverse effects. Neurosurgical Procedures / methods. Preoperative Care / methods. Probability. Prognosis. Prospective Studies. Reference Values. Risk Assessment. Survival Rate. Treatment Outcome. Vancomycin / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094103.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 140QMO216E / Metronidazole; 6Q205EH1VU / Vancomycin; 9M416Z9QNR / Ceftazidime
  •  go-up   go-down


73. Pinheiro AD, Foote RL, McCaffrey TV, Kasperbauer JL, Bonner JA, Olsen KD, Cha SS, Sargent DJ: Intraoperative radiotherapy for head and neck and skull base cancer. Head Neck; 2003 Mar;25(3):217-25; discussion 225-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiotherapy for head and neck and skull base cancer.
  • BACKGROUND: The purpose of this study was to evaluate the use of intraoperative electron beam radiotherapy (IORT) as an adjuvant modality in the treatment of advanced head and neck and skull base cancer.
  • METHODS: Between 1991 and 1996, 34 patients with squamous cell carcinoma (SCCA) and 10 patients with non-SCCA were enrolled in this prospective nonrandomized clinical trial.
  • Most patients had been previously treated with combinations of surgery, external beam radiotherapy, and chemotherapy.
  • The most frequent sites treated were the skull base (56%) and the neck (44%).
  • IORT was delivered in a dedicated operating room suite with energies of 6 to 15 MeV (6 MeV most commonly used) at doses of 12.5 to 22.5 Gy.
  • RESULTS: At 2 years overall and disease-free survival was 32% and 21%, respectively, for the SCCA patients and 50% and 40%, respectively, for the non-SCCA patients.
  • Tumor control rates at 2 years in the IORT field were 46% for the SCCA patients and 52% for the non-SCCA patients.
  • For squamous cell histology, survival in patients with microscopic residual tumor did not differ from those with no residual tumor, but they both had significantly longer disease-free survival than those patients with gross residual at the time of IORT (p =.03), with a trend toward longer overall survival (p =.09).
  • The only complication directly attributable to IORT was a neuropathy in a patient who received an IORT dose of 22.5 Gy (cumulative dose 130.1 Gy).
  • CONCLUSIONS: IORT at a dose of 12.5 Gy is safe and produces tumor control and survival for patients likely to have microscopic residual disease in sites difficult to resect such as the skull base.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Intraoperative Care / methods. Skull Base Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Female. Humans. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Radiation Dosage. Radiotherapy, Adjuvant. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 217-226, 2003
  • (PMID = 12599289.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Motegi H, Terasaka S, Yamaguchi S, Kobayashi H, Asaoka K, Iwasaki Y: [A case of catecholamine-secreting glomus jugulare tumor: treatment strategy and perioperative management]. No Shinkei Geka; 2008 Nov;36(11):1029-34
Hazardous Substances Data Bank. Norepinephrine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of catecholamine-secreting glomus jugulare tumor: treatment strategy and perioperative management].
  • Advances of neuroimaging, skull base technique and embolization improved outcome in patients who present with tumor of the glomus jugulare.
  • The authors present detailed description of treatment strategies and perioperative management with a catecholamine secreting glomus jugulare.
  • A 57-year-old woman, in whom the noradrenaline level in plasma was twenty times higher than normal, presented with uncontrolled labile hypertension and carcinoid syndrome.
  • Magnetic resonance imaging (MRI) and 123I-meta-iodobenzylguanidine (MIBG) scan depicted the tumor as originating from the jugular foramen extending to the infratemporal fossa.
  • Alpha catecholamine blocker and magnesium sulfate treatment was commenced prior to embolization and surgery.
  • Under cranial nerve and hemodynamic monitoring, tumor resection via the infratemporal fossa type A was performed.
  • The patient remained hemodynamically stable and the lower cranial nerve injury was able to be avoided.
  • We emphasize treatment strategy, intra- and perioperative management of this rare entity.
  • [MeSH-major] Glomus Jugulare Tumor / therapy
  • [MeSH-minor] Catecholamines / secretion. Female. Humans. Hypertension / drug therapy. Hypertension / etiology. Middle Aged. Norepinephrine / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048923.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Catecholamines; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


75. Sparano A, Kreiger P, Kazahaya K: Malignant rhabdoid tumor of the parapharyngeal space. Ear Nose Throat J; 2009 Mar;88(3):E24-6
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumor of the parapharyngeal space.
  • Malignant rhabdoid tumor has been a somewhat controversial entity since it was first described in 1978 as a possible sarcomatous variant of Wilms tumor.
  • Eventually, however, it was found to be a distinct neoplastic tumor with histologic characteristics similar to those of rhabdomyosarcoma.
  • Malignant rhabdoid tumors affect children.
  • Associated mortality is significant, even with combined-modality treatment regimens.
  • We describe the case of a large extrarenal malignant rhabdoid tumor of the parapharyngeal space with extension to the infratemporal fossa and skull base in a previously healthy 2-year-old girl who had presented with a cervical mass and ipsilateral Horner syndrome.
  • The patient underwent complete surgical extirpation of the lesion and received adjunctive cisplatin chemotherapy and radiation therapy, and she remained disease-free at 9 months of follow-up.
  • Given the age group of the patients that these neoplasms most commonly affect and given the neoplasms' resemblance to rhabdomyosarcoma and other small round-cell tumors of the head and neck, discussion of the associated clinical pathology, imaging characteristics, histopathologic features, and mode of management are of particular importance, especially so in view of the uncommon location of the tumor in this specific case.
  • Such a discussion may help lead to minimization of misdiagnosis and maximization of therapeutic benefit.
  • [MeSH-major] Pharyngeal Neoplasms / pathology. Rhabdoid Tumor / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291622.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Lund V, Howard DJ, Wei WI: Endoscopic resection of malignant tumors of the nose and sinuses. Am J Rhinol; 2007 Jan-Feb;21(1):89-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of malignant tumors of the nose and sinuses.
  • BACKGROUND: Since the introduction of endoscopic surgery, its role has been gradually extended to encompass a range of pathologies, including sinonasal tumors, facilitated by the ability to repair significant skull-base defects.
  • However, the rarity and long natural history of malignant tumors make it difficult to accrue cohorts comparable with the established gold standard of craniofacial resection.
  • METHODS: In this prospective cohort study, after histological confirmation and a staging imaging protocol, patients deemed suitable were offered the option of an entirely endoscopic resection as an alternative to craniofacial resection.
  • The procedure was performed under frozen section control.
  • Thirty-seven cases underwent radiotherapy and 14 cases underwent adjuvant chemotherapy.
  • A wide range of pathologies included 15 cases of adenocarcinoma, 11 malignant melanomas, and 11 olfactory neuroblastomas.
  • Thirty-six patients are alive and well, 7 patients have residual disease, 4 patients are dead of disease, and 2 patients have died of intercurrent disease.
  • [MeSH-major] Endoscopy / methods. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Length of Stay. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Survival Rate. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283568.001).
  • [ISSN] 1050-6586
  • [Journal-full-title] American journal of rhinology
  • [ISO-abbreviation] Am J Rhinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Hallacq P, Labrousse F, Roullet B, Orsel S, Bessede JP, Moreau JJ: [Adenoid cystic carcinomas invading the skull base. Apropos of 4 cases and review of the literature]. Neurochirurgie; 2001 Dec;47(6):542-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinomas invading the skull base. Apropos of 4 cases and review of the literature].
  • [Transliterated title] Carcinomes adénoïdes kystiques envahissant la base du crâne. A propos de 4 observations et revue de la littérature.
  • Head and neck adenoid cystic carcinomas may invade the adjacent skull base by bone lysis and/or by perinervous and perivascular spread within the skull base foramina.
  • Neurosurgical decision making is not well defined regarding the extent of intracranial tumor component removal, as neurosurgical expertise is limited for this peculiar type of tumors.
  • The issue is to decide whether a radical supposedly locally curative surgery should be attempted, or if a large non disfigurating surgery is mandatory, keeping in mind the frequency of local recurrences and of distant metastases.
  • Over a 13-year period, four adenoid cystic carcinomas invading the skull base were operated on at our institution: two tumors originated in the parotid gland, one in the sphenoid sinus, and one in the ethmoid sinus.
  • One patient with advanced metastatic disease was submitted to chemotherapy.
  • Three patients died from local tumor progression and distant metastases within three years after the intracranial tumor extension has been diagnosed.
  • The patient with an ethmoid tumor is still alive seven years after surgery without any evidence of local tumor progression nor distant metastases.
  • Surgery remains the gold standard treatment for adenoid cystic carcinomas invading the skull base.
  • However, in our opinion a large tumor removal, without or with bone osteotomies, but without sacrifice of cranial nerves, cavernous sinus, internal carotid artery, and of the orbit allows patient survival with an acceptable comfort and absence of psychological distress due to disfigurating surgery nor surgically induced neurological functional deficit.
  • The place of chemotherapy has, yet, to be determined.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Ethmoid Sinus / surgery. Paranasal Sinus Neoplasms / surgery. Parotid Neoplasms / surgery. Skull Base Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915613.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


78. De Paula AM, André N, Fernandez C, Coulibaly B, Scavarda D, Lena G, Bouvier C: Solitary, extracutaneous, skull-based juvenile xanthogranuloma. Pediatr Blood Cancer; 2010 Aug;55(2):380-2
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary, extracutaneous, skull-based juvenile xanthogranuloma.
  • We report a case of an 18-month-old female who presented an occipital bone lesion with progressive growth.
  • Imaging studies showed a left extradural, skull-based tumor partially occupying the posterior fossa.
  • Partial surgical resection, chemotherapy, and conformational radiotherapy were used.
  • Exclusive extracutaneous JXG with an intracranial, vertebral, or skull-based localization is extremely rare.
  • [MeSH-major] Bone Neoplasms / diagnosis. Xanthogranuloma, Juvenile / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnostic Imaging. Female. Humans. Infant. Skull Base. Treatment Outcome


79. Koch M, Constantinidis J, Dimmler A, Strauss C, Iro H: [Long-term experiences in the therapy of esthesioneuroblastoma]. Laryngorhinootologie; 2006 Oct;85(10):723-30
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term experiences in the therapy of esthesioneuroblastoma].
  • [Transliterated title] Langzeit-Erfahrungen in der Therapie des Asthesioneuroblastoms.
  • BACKGROUND: Esthesioneuroblastoma is a rare and clinically variable tumor of nasal sinus and skull base and challenging for modern multidisciplinary therapy.
  • There are no generally known prognostic factors or generally accepted standard therapy regimens.
  • According to the classification of Kadish 1 patient (4 %) had stage A, 16 patients (53 %) stage B and 11 cases (43 %) had stage C tumors.
  • Tumors were in 12 patients (52 %) graded I or II and in 10 cases tumors had grade III or IV (48 %).
  • Operative therapy was performed in 23 patients (88.5 %), being in 5 patients a single mode therapy.
  • In 18 cases combined therapy was performed (surgery and radiotherapy or radiotherapy and chemotherapy).
  • Disease specific 10- and 15-year-survival according to the estimation of Kaplan-Meier was 76.2 %.
  • Patients with small tumors (Kadish A/B) had a 15-year-survival of 86.7 % compared to 63.6 % in cases with advanced tumors (Kadish C).
  • In 7 cases (26.9 %) recurrences developed.
  • Salvage therapy was performed in 5 cases (71.4 %) with a success rate and a 15-year survival each of 60 %.
  • CONCLUSIONS: Therapy of esthesioneuroblastoma is challenging because of rarity and biologic variability of the tumor and and because of lack of a standard therapy.
  • An interdisciplinary multimodal therapeutic approach is necessary especially in case of advanced tumors with promising results.
  • Histopathological grading according to Hyams and tumor stage are important factors for survival and prognosis.
  • Although recurrence can occur with high frequency even after prolonged time interval, long time survival can be improved after aggressive salvage therapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Dactinomycin / administration & dosage. Dactinomycin / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Time Factors. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673299.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide; VAIA protocol
  •  go-up   go-down


80. Ishikura R, Ando K, Nagami Y, Yamamoto S, Miura K, Pande AR, Yamano T, Hirota S, Nakao N: Evaluation of vascular supply with cone-beam computed tomography during intraarterial chemotherapy for a skull base tumor. Radiat Med; 2006 Jun;24(5):384-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of vascular supply with cone-beam computed tomography during intraarterial chemotherapy for a skull base tumor.
  • A cone-beam lowers the X-ray exposure level and the contrast material dose used compared to those for the conventional angiography-computed tomography (angio-CT) technique.
  • Herein we present a patient with a metastatic skull base bone tumor in which the subtraction image of cone-beam CT with a flat panel detector was useful for evaluating the vascular supply during superselective intraarterial chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Skull Base Neoplasms / drug therapy. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Carotid Artery, External / diagnostic imaging. Combined Modality Therapy. Humans. Injections, Intra-Arterial. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1995 Nov;165(5):1269-72 [7572516.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1176-86 [15895601.001]
  • [Cites] Diagn Interv Radiol. 2005 Mar;11(1):10-3 [15795836.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):419-22 [7977964.001]
  • [Cites] Comput Med Imaging Graph. 2002 May-Jun;26(3):153-8 [11918976.001]
  • [Cites] Radiat Med. 2003 Jan-Feb;21(1):17-22 [12801139.001]
  • [Cites] Dentomaxillofac Radiol. 2004 Sep;33(5):285-90 [15585803.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 May;19(5):935-41 [9613516.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Jan;25(1):74-6 [14729532.001]
  • [Cites] Radiother Oncol. 2005 Jun;75(3):279-86 [15890424.001]
  • [Cites] Cardiovasc Intervent Radiol. 1999 May-Jun;22(3):201-5 [10382049.001]
  • (PMID = 16958419.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


81. Strek P, Zagólski O, Składzień J, Przeklasa R, Blaschke J, Białas M, Urbanik A: [Olfactory neuroblastoma removed under endoscopic guidance]. Otolaryngol Pol; 2006;60(3):433-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Olfactory neuroblastoma is a rare tumour associated with high rates of recurrence and mortality.
  • Treatment includes surgery, radiotherapy, chemotherapy, or a combination.
  • The ideal treatment modality has yet to be determined.
  • During surgery, a 5 mm in diameter tumour was identified in the left superior nasal meatus.
  • The tumour was classified according to Kadish as stage A, according to Biller as T1.
  • MR scans performed two months later disclosed pathological tissues in the left ethmoid region.
  • RESULTS: Multiple biopsies taken on subsequent frontosphenoethmoidectomy did not contain tumour cells.
  • CONCLUSIONS: The exclusively surgical treatment proved effective due to early stage of the tumour and no evidence of infiltration of the frontal skull base.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity / surgery. Nose Neoplasms / surgery
  • [MeSH-minor] Endoscopy. Ethmoid Sinusitis / etiology. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989461.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


82. Johnson MD, Sade B, Milano MT, Lee JH, Toms SA: New prospects for management and treatment of inoperable and recurrent skull base meningiomas. J Neurooncol; 2008 Jan;86(1):109-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New prospects for management and treatment of inoperable and recurrent skull base meningiomas.
  • Skull base, including optic nerve, cavernous sinus, clival and foramen magnum tumors represent a major challenge for neurosurgeons and neuro-oncologists.
  • Growth regulatory signaling pathways for these tumors are of increasing interest as potential targets for new chemotherapy.
  • This article reviews some recent findings pathways that appear to regulate meningioma growth.
  • Potential targets for novel therapies are also discussed.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy. Skull Base Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2001 May;48(5):1022-30; discussion 1030-2 [11334268.001]
  • [Cites] Mol Pharmacol. 1998 Dec;54(6):1007-15 [9855629.001]
  • [Cites] Surg Neurol. 2006 Jan;65(1):28-33; discussion 33-4 [16378847.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):431-7 [11485901.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):668-75 [12296652.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):8-20; discussion 20-1 [11546562.001]
  • [Cites] Surg Neurol. 2005;64 Suppl 2:S58-66 [16256845.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):580-92 [12957272.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):967-75 [9392533.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4074-82 [15930342.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] Acta Neurochir (Wien). 2005 Apr;147(4):367-74; discussion 374-5 [15696264.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):148-52 [16871891.001]
  • [Cites] Curr Treat Options Oncol. 2006 Jul;7(4):285-94 [16916489.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9185-9 [8090789.001]
  • [Cites] Br J Cancer. 1994 May;69(5):952-6 [8180030.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] Neurosurg Rev. 2004 Oct;27(4):238-45 [15168138.001]
  • [Cites] AJNR Am J Neuroradiol. 1986 Sep-Oct;7(5):963-72 [3096121.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):610-4 [9322850.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1478-83 [9119990.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1068-75 [15509313.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1505-8 [2493982.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):861-9 [15613459.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1411-23 [9811332.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] J Neurosurg. 1996 Jan;84(1):20-8 [8613831.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):578-87 [9055299.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Biochem J. 1999 Jan 15;337 ( Pt 2):171-7 [9882612.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Neurosurgery. 2006 Jan;58(1):28-36; discussion 28-36 [16385326.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1314-24 [15519805.001]
  • [Cites] Radiother Oncol. 1999 Feb;50(2):145-50 [10368037.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):208-14 [16509494.001]
  • [Cites] Biochim Biophys Acta. 1994 Dec 30;1198(2-3):131-47 [7819271.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):99-102 [9916799.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Clin Neurol Neurosurg. 2006 Jul;108(5):470-6 [16191463.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):689-708 [15613446.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):750-5 [2213165.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] J Neurosurg. 1983 Jun;58(6):824-31 [6854374.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):215-22 [15735908.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):133-42 [11995814.001]
  • [Cites] Stereotact Funct Neurosurg. 1991;57(1-2):99-105 [1667045.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):933-40 [10526074.001]
  • [Cites] Folia Neuropathol. 2006;44(2):111-5 [16823693.001]
  • [Cites] Biochem J. 2000 Oct 15;351 Pt 2:289-305 [11023813.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):99-109 [12504041.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] Prog Neurol Surg. 2007;20:142-9 [17317982.001]
  • [Cites] Neurologist. 2004 May;10(3):113-30 [15140272.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):431-6 [14706335.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):491-7 [16235682.001]
  • [Cites] Nat Med. 2002 Mar;8(3):289-93 [11875501.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4141-7 [9307305.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2):163-73 [17219818.001]
  • [Cites] Radiother Oncol. 2003 Nov;69(2):177-82 [14643955.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):1109-20; discussion 1120-1 [17143245.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Oncologist. 2005 Sep;10 (8):565-78 [16177281.001]
  • [Cites] Neurosurgery. 2005 Mar;56(3):546-59; discussion 546-59 [15730581.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Mar;123(3):453-8 [1124827.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Acta Neurochir (Wien). 2001 Aug;143(8):749-57; discussion 758 [11678395.001]
  • [Cites] Mol Cell Biol. 1989 Jul;9(7):2934-43 [2550789.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1425-30 [16170090.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Radiother Oncol. 2004 Jun;71(3):251-8 [15172139.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):1-7 [16703453.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):504-12 [10850863.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5355-62 [15289342.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Neurosurgery. 1999 Mar;44(3):579-87; discussion 587-8 [10069595.001]
  • [Cites] Front Radiat Ther Oncol. 1999;33:305-14 [10549500.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Neurol Res. 1989 Mar;11(1):9-13 [2565555.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(6):555-62 [11534672.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):45-51 [8583244.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):202-8 [8283257.001]
  • [Cites] BMC Cancer. 2006 May 18;6:133 [16709245.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] J Neurooncol. 1991 Jun;10(3):233-40 [1910078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1412-22 [16029801.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1822-9 [15753380.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):590-7 [9418905.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):567-74; discussion 574-5 [10719852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1427-31 [16029803.001]
  • [Cites] Neurosurgery. 2005;56(1):155-62; discussion 162 [15617598.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] J Clin Neurosci. 1999 Jan;6(1):27-30 [10833567.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1685-700 [12175684.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):601-6 [9426397.001]
  • [Cites] FASEB J. 1995 Oct;9(13):1311-8 [7557021.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Ann Med. 2006;38(3):200-11 [16720434.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):8856-64 [11134009.001]
  • [Cites] Int J Dev Neurosci. 1999 Apr;17(2):131-4 [10221672.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Neurosurgery. 2006 Dec;59(6):1177-85; discussion 1185-7 [17277680.001]
  • [Cites] Surg Neurol. 2004 Oct;62(4):332-8; discussion 338-40 [15451280.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):63-8 [17225937.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):525-6; author reply 525-6 [16452568.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):59-71 [15784165.001]
  • [Cites] Cell Signal. 2002 May;14(5):381-95 [11882383.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1177-81 [12654424.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1371-80 [11121636.001]
  • [Cites] J Neurosurg. 1991 Aug;75(2):177-80 [2072155.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):333-8 [15674748.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(4):194-5 [15557769.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11 [15093905.001]
  • [Cites] J Neurosurg. 2004 Dec;101(6):951-9 [15597756.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5863-7 [2393856.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41807-14 [15258148.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1024-8 [10973323.001]
  • [Cites] Cell. 1993 Jan 29;72 (2):269-78 [8381049.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Int J Cancer. 1991 Sep 30;49(3):398-402 [1917138.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12 ):880-7 [15956649.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Biochim Biophys Acta. 1999 Mar 25;1423(2):M29-36 [10214350.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • (PMID = 17624496.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 163
  •  go-up   go-down


83. Minovi A, Basten O, Hunter B, Draf W, Bockmühl U: Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck; 2007 May;29(5):439-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review.
  • BACKGROUND: This study analyzes the management and outcomes of a series of 10 malignant peripheral nerve sheath tumors (MPNST) of the head and neck.
  • METHODS: From 1984 to 2004, 10 patients underwent surgical treatment of a MPNST.
  • RESULTS: Eight tumors were located at the lateral skull base; 2 involved the vagus nerve in isolation.
  • Seventy percent of the tumors could be resected completely.
  • Long-term follow-up showed a 2-year disease-specific survival rate of 50% and 5-year survival rate of 20%.
  • Negative prognostic indicators were advanced tumor stage, early recurrence, and presumably also the presence of von Recklinghausen's disease.
  • CONCLUSIONS: Although rare, MPNST is one of the most aggressive tumors in the head and neck area.
  • Complete tumor removal is the mainstay of treatment and most important prognostic factor of MPNST.
  • The role of adjuvant chemotherapy remains controversial.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17163467.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


84. Tamura S, Tamura Y, Ohoka A, Hasegawa T, Uchida K: A canine case of skull base meningioma treated with hydroxyurea. J Vet Med Sci; 2007 Dec;69(12):1313-5
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A canine case of skull base meningioma treated with hydroxyurea.
  • An 11-year-old female miniature schnauzer was tentatively diagnosed with the skull base meningioma, based on several examinations.
  • Because surgical treatment was difficult, and outpatient radiation therapy was not available in the local area, chemotherapy with hydroxyurea combined with dexamethasone was selected.
  • The patient's clinical symptoms improved after one week of treatment, and the tumor size was obviously reduced on MRI performed 37 days after treatment began.
  • The patient received hydroxyurea for 7 months, with symptoms remaining stable, and the tumor re-increased to almost the same size at 7 months as that at the initial examination.
  • At that time, hydroxyurea was discontinued.
  • The patient died from pulmonary edema 14 months after treatment began.
  • Pathologically, the tumor was diagnosed as a meningioma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176033.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


85. Meyers CA, Geara F, Wong PF, Morrison WH: Neurocognitive effects of therapeutic irradiation for base of skull tumors. Int J Radiat Oncol Biol Phys; 2000 Jan 1;46(1):51-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive effects of therapeutic irradiation for base of skull tumors.
  • PURPOSE: To determine whether radiation therapy delivered to the paranasal sinuses causes any long-term impairment in neurocognitive function as a result of incidental brain irradiation.
  • The median radiation dose was 60 Gy (range 50-68 Gy) in fractions of 1.8 to 2 Gy.
  • The volume of irradiated brain was calculated from planning computed tomography slices or simulation films.
  • Three patients also developed pituitary dysfunction.
  • Neurocognitive symptoms were related to the total dose of radiation delivered but not to the volume of brain irradiated, side of radiation boost, or chemotherapy treatment.
  • CONCLUSIONS: Radiation therapy for paranasal sinus cancer may cause delayed neurocognitive side effects.
  • [MeSH-major] Brain / radiation effects. Cognition Disorders / etiology. Radiation Injuries / etiology. Skull Base Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Ethmoid Sinus. Female. Humans. Magnetic Resonance Imaging. Male. Maxillary Sinus Neoplasms / radiotherapy. Middle Aged. Neuropsychological Tests. Paranasal Sinus Neoplasms / radiotherapy. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10656372.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


86. Laigle-Donadey F, Taillibert S, Martin-Duverneuil N, Hildebrand J, Delattre JY: Skull-base metastases. J Neurooncol; 2005 Oct;75(1):63-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull-base metastases.
  • Metastasis to the skull-base particularly affects patients with carcinoma of the breast and prostate.
  • Clinically, the key feature is progressive ipsilateral involvement of cranial nerves.
  • Five syndromes have been described according to the metastatic site including the orbital, parasellar, middle-fossa, jugular foramen and occipital condyle syndromes.
  • The treatment depends on the nature of the underlying tumor.
  • Radiotherapy is generally the standard treatment, while some patients with chemosensitive or hormonosensitive lesions benefit from chemotherapy or hormonotherapy and selected patients from surgical removal.
  • Gamma Knife radiosurgery is sometimes a useful alternative, particularly for previously irradiated skull-base regions, and for small tumors (diameter < 30 mm).
  • The overall prognosis is poor, with an overall median survival of about 2.5 years, probably because skull-base metastases appear late in the course of the disease.
  • [MeSH-major] Skull Base Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1964 Jun;21:447-60 [14171303.001]
  • [Cites] Can J Neurol Sci. 1985 Nov;12(4):336-40 [4084873.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):352-8 [3661836.001]
  • [Cites] No Shinkei Geka. 1987 Jul;15(7):765-9 [3670546.001]
  • [Cites] Rev Neurol. 1997 Jul;25(143):1092-4 [9280644.001]
  • [Cites] Cancer. 1987 Jun 1;59(11):1887-91 [3567852.001]
  • [Cites] J Neurol. 1998 Feb;245(2):98-100 [9507415.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 Sep;2(5):423-31 [12169223.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1990 Jul;53(7):613-4 [2391528.001]
  • [Cites] Arch Intern Med. 1963 Dec;112:819-21 [14056846.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;72 Suppl 1:81-7 [10681695.001]
  • [Cites] Clin Radiol. 1998 Jun;53(6):405-16 [9651055.001]
  • [Cites] Neurology. 1990 Jun;40(6):997-9 [2345622.001]
  • [Cites] HNO. 2002 Feb;50(2):165-8 [12080628.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):586-9 [2297648.001]
  • [Cites] Hong Kong Med J. 2002 Feb;8(1):48-51 [11861994.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):877-81 [1643620.001]
  • [Cites] Headache. 2002 Feb;42(2):142-6 [12005291.001]
  • [Cites] J Clin Neuroophthalmol. 1992 Sep;12(3):149-53 [1401157.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1973 Apr;36(2):211-6 [4708456.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Nov;32(12):908-10 [1282684.001]
  • [Cites] Arch Neurol. 1983 Dec;40(13):816-8 [6639410.001]
  • [Cites] Br J Urol. 1988 May;61(5):441-4 [3395804.001]
  • [Cites] Arch Neurol. 1996 Jun;53(6):561-6 [8660159.001]
  • [Cites] Can J Neurol Sci. 1985 Nov;12(4):327-31 [4084871.001]
  • [Cites] Neurology. 1992 Jun;42(6):1181-4 [1603345.001]
  • [Cites] No Shinkei Geka. 1996 Sep;24(9):829-33 [8827733.001]
  • [Cites] J Assoc Physicians India. 2000 Aug;48(8):850-1 [11273489.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):783-6; discussion 786 [1407469.001]
  • [Cites] Radiology. 1979 Feb;130(2):465-8 [104361.001]
  • [Cites] Neurochirurgie. 2001 Feb;47(1):61-5 [11283458.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):997-1003 [9169805.001]
  • [Cites] No To Shinkei. 1980 Jul;32(7):695-700 [7407020.001]
  • [Cites] Neurology. 1981 Aug;31(8):998-1002 [7196526.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):180-4 [6850542.001]
  • [Cites] Australas Radiol. 2001 Nov;45(4):534-5 [11903195.001]
  • [Cites] Am J Ophthalmol. 1995 Jun;119(6):779-85 [7785694.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Sep;102(3):149-55 [10996713.001]
  • [Cites] J Korean Med Sci. 2000 Jun;15(3):363-7 [10895984.001]
  • [Cites] Rev Neurol. 1999 Nov 16-30;29(10 ):929-32 [10637842.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):674-6 [12507118.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 1998 Oct;78(10):761-2 [11038829.001]
  • [Cites] Naika. 1970 Oct;26(4):755-7 [5470882.001]
  • [Cites] Neurology. 1981 May;31(5):530-7 [6972014.001]
  • [Cites] Arch Ophthalmol. 1988 Oct;106(10):1403-8 [3178551.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1985 Dec;48(12):1305-6 [4087010.001]
  • [Cites] Neurologia. 1989 Oct;4(8):277-81 [2637769.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2000 Jun;91(6):562-4 [10897582.001]
  • [Cites] Eye (Lond). 2002 Nov;16(6):749-53 [12439671.001]
  • [Cites] Headache. 1998 Apr;38(4):308-11 [9595872.001]
  • [Cites] Cancer. 1983 Nov 1;52(9):1739-47 [6616423.001]
  • [Cites] HNO. 2001 Feb;49(2):126-9 [11270194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):977-81 [9392534.001]
  • [Cites] Arch Ophthalmol. 1974 Oct;92(4):276-86 [4412321.001]
  • [Cites] J Neurosurg. 1981 Sep;55(3):463-6 [7264738.001]
  • [Cites] Intern Med. 2001 Sep;40(9):924-30 [11579958.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Jul;105(3):170-4 [12860509.001]
  • [Cites] Ann Nucl Med. 1998 Aug;12 (4):213-6 [9795708.001]
  • [Cites] Ann Intern Med. 1969 Jan;70(1):49-54 [4303303.001]
  • [Cites] Urology. 1988 Mar;31(3):211-3 [3126588.001]
  • [Cites] Arch Soc Esp Oftalmol. 2003 Jan;78(1):43-6 [12571774.001]
  • [Cites] J Comput Assist Tomogr. 1985 Jan-Feb;9(1):115-20 [2981908.001]
  • [Cites] Neurology. 1963 Sep;13:797-809 [14064314.001]
  • [Cites] Orbit. 2002 Dec;21(4):307-10 [12610771.001]
  • [Cites] J Neurosurg. 1985 May;62(5):776-80 [3989599.001]
  • [Cites] Neurologia. 1989 Oct;4(8):293-5 [2637770.001]
  • [Cites] Am J Ophthalmol. 2002 Nov;134(5):785-7 [12429268.001]
  • [Cites] Cancer. 1970 Feb;25(2):478-80 [5413515.001]
  • [Cites] Neurology. 1986 Jun;36(6):745-9 [3703281.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Jan;123(1):13-21 [164131.001]
  • [Cites] Actas Urol Esp. 1994 Oct;18(9):911-4 [7817864.001]
  • [Cites] No Shinkei Geka. 1996 Mar;24(3):235-9 [8851952.001]
  • [Cites] South Med J. 1984 Jan;77(1):92-3 [6695231.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 May;47(5):558-60 [6547477.001]
  • [Cites] Neurology. 1981 Oct;31(10):1277-81 [6287347.001]
  • [Cites] Can J Neurol Sci. 1985 Nov;12(4):363-5 [3936612.001]
  • [Cites] Arch Neurol. 1980 Jan;37(1):59-61 [7350906.001]
  • [Cites] Cancer. 1994 May 1;73(9):2395-9 [8168043.001]
  • [Cites] Isr Med Assoc J. 2002 Oct;4(10):829-31 [12389355.001]
  • [Cites] Br J Radiol. 1999 Oct;72 (862):933-41 [10673942.001]
  • [Cites] Neurologia. 2000 Jan;15(1):31 [10730064.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):874-5 [8431871.001]
  • [Cites] J Neurol Sci. 1997 May 1;148(1):127-9 [9125401.001]
  • [Cites] Radiographics. 1997 Sep-Oct;17 (5):1111-21 [9308105.001]
  • [Cites] Br J Ophthalmol. 1988 Apr;72 (4):248-52 [3288277.001]
  • [Cites] Surg Neurol. 2003 Sep;60(3):219-25; discussion 225-6 [12922038.001]
  • (PMID = 16215817.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


87. Sampath P, Park MC, Huang D, Deville C, Cortez S, Chougule P: Esthesioneuroblastoma (olfactory neuroblastoma) with hemorrhage: an unusual presentation. Skull Base; 2006 Aug;16(3):169-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esthesioneuroblastoma (olfactory neuroblastoma) is an uncommon neuroectodermal tumor.
  • Its biological activity ranges from indolent growth to local recurrence and rapid widespread metastasis.
  • Treatment options consist of surgical resection followed by radiation therapy for primary lesions and the addition of chemotherapy for advanced, recurrent, or metastatic lesions.
  • Imaging showed a large frontal skull-based tumor associated with intratumoral hemorrhage.
  • The findings prompted an emergent combined anterior craniofacial resection with gross total resection of the tumor.
  • Postoperatively, she received adjuvant intensity-modulated radiation therapy and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Head Neck. 2000 Sep;22(6):550-8 [10941155.001]
  • [Cites] Neurosurg Clin N Am. 2000 Oct;11(4):693-701 [11082179.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 May;130(5):567-74 [15138422.001]
  • [Cites] Laryngoscope. 1990 Oct;100(10 Pt 1):1052-8 [2215035.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] Cancer. 1979 Sep;44(3):1087-94 [383268.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1977 Nov-Dec;86(6 Pt 1):760-5 [596773.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):114-8 [7558807.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):35-43 [8583243.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Ear Nose Throat J. 1998 Nov;77(11):890-1 [9846465.001]
  • (PMID = 17268590.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1586171
  •  go-up   go-down


88. Higurashi M, Yagishita S, Fujitsu K, Kitsuta Y, Takemoto Y, Osano S: Plasma cell myeloma of the skull base: report of two cases. Brain Tumor Pathol; 2004;21(3):135-41
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell myeloma of the skull base: report of two cases.
  • Plasma cell myeloma (PCM) of the skull base is rarely encountered in neurosurgical practice.
  • PCM has a wide spectrum of pathology, including a quite benign, solitary plasmacytoma (SPC), and an extremely malignant, multiple myeloma (MM) at the two ends of the spectrum.
  • We have described two patients with PCM of the skull base, of which one harbored SPC, and the other progressed to MM.
  • In case 1, a 46-year-old man presented with left multiple cranial nerve impairments and had a large skull base tumor.
  • The specimen and general examination, including bone marrow aspiration, revealed SPC.
  • The specimen revealed a plasmablastic tumor, i.e., myeloma.
  • She was administrated adjuvant chemotherapy and autologous bone marrow transplantation.
  • [MeSH-major] Multiple Myeloma / pathology. Plasmacytoma / pathology. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696975.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • There were 25 squamous cell carcinomas, 14 undifferentiated carcinomas, 31 minor salivary gland tumors (adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma), 8 esthesioneuroblastomas, and 1 transitional cell carcinoma.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • RESULTS: The 5-year actuarial local control rate for stage I (limited to the site of origin; 22 patients) was 86%; for stage II (extension to adjacent sites (eg, adjacent sinuses, orbit, pterygomaxillary fossa, nasopharynx; 21 patients) was 65%; and for stage III (destruction of skull base or pterygoid plates, or intracranial extension; 35 patients) was 34%.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • Most patients who received elective neck irradiation (57%) had stage III disease.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • Elective neck irradiation is probably unnecessary for patients with early-stage disease.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Singh AD, Chacko AG, Chacko G, Rajshekhar V: Plasma cell tumors of the skull. Surg Neurol; 2005 Nov;64(5):434-8; discussion 438-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell tumors of the skull.
  • BACKGROUND: Plasma cell tumors are rare neoplasms, which include extramedullary plasmacytoma, solitary plasmacytoma of the bone, and multiple myeloma.
  • Although indistinguishable histopathologically, these entities need to be differentiated as treatment and prognosis vary.
  • METHODS: This study was conducted by retrospective chart review and correspondence with patients diagnosed to have plasma cell tumors of the skull from 1992 to 2004.
  • The clinico-diagnostic investigations, treatment, and subsequent follow-up of the patients were obtained.
  • RESULTS: We report 5 cases of plasma cell tumors of the skull.
  • The lesion involved the base of skull in 2 and the calvarium in 3 patients.
  • The above 3 patients underwent radiation, followed by chemotherapy, and there was improvement in their neurologic status at subsequent follow-up.
  • Another patient with a scalp swelling and symptoms of systemic involvement underwent investigations to detect multiple myeloma and, hence, was not subjected to an invasive procedure for histopathologic diagnosis.
  • Chemotherapy was initiated but was discontinued because of social reasons.
  • CONCLUSION: The treatment options are different for the systemic form of disease and the localized disease; hence, it is imperative that a rigorous search for systemic involvement is conducted in a case of solitary or extramedullary plasmacytoma.
  • [MeSH-major] Plasmacytoma / pathology. Plasmacytoma / surgery. Skull Neoplasms / pathology. Skull Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253694.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina Dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck; 2005 Jul;27(7):575-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study.
  • BACKGROUND: Malignant tumors of the superior sinonasal vault are rare, and, because of this and the varied histologic findings, most outcomes data reflect the experience of small patient cohorts.
  • This International Collaborative study examines a large cohort of patients accumulated from multiple institutions experienced in craniofacial surgery, with the aim of reporting benchmark figures for outcomes and identifying patient-related and tumor-related predictors of prognosis after craniofacial resection (CFR).
  • One hundred eighty-eight patients (56.3%) had had prior single-modality or combined treatment, which included surgery in 120 (36%), radiation in 79 (23.7%), and chemotherapy in 56 (16.8%).
  • Adjuvant radiotherapy was given in 161 (48.2%) and chemotherapy in 16 (4.8%).
  • Statistical analyses for outcomes were performed in relation to patient characteristics, tumor characteristics, including histologic findings and extent of disease, surgical resection margins, prior radiation, and prior chemotherapy to determine predictive factors.
  • The 5-year overall, disease-specific, and recurrence-free survival rates were 48.3%, 53.3%, and 45.8%, respectively.
  • The status of surgical margins, histologic findings of the primary tumor, and intracranial extent were independent predictors of overall, disease-specific, and recurrence-free survival on multivariate analysis.
  • CONCLUSIONS: CFR for malignant paranasal sinus tumors is a safe surgical treatment with an overall mortality of 4.5% and complication rate of 33%.
  • The status of surgical margins, histologic findings of the primary tumor, and intracranial extent are independent predictors of outcome.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Paranasal Sinus Neoplasms / surgery. Skull / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Follow-Up Studies. Humans. International Cooperation. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Postoperative Complications. Skull Base / pathology. Skull Base / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825201.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


92. Kilgore S, Prayson RA: Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann Diagn Pathol; 2002 Aug;6(4):222-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic and proliferative markers in chordomas: a study of 26 tumors.
  • This study retrospectively reviews the clinicopathologic features of 26 chordomas and examines MIB-1, p53, bcl-2, and cyclin D1 immunoreactivity in these neoplasms.
  • Sixteen tumors arose in the lumbosacral region and 10 in the clivus.
  • Marked nuclear pleomorphism was identified in seven tumors.
  • Marked hypercellularity was seen in two tumors.
  • Focal necrosis was identified in seven tumors.
  • MIB-1 labeling indices (LI) in 22 tumors ranged from 0 to 3.8 (mean, 0.5).
  • Seven tumors had positive p53 immunostaining and three demonstrated focal positive staining with bcl-2 antibody.
  • Five tumors locally recurred; two patients developed metastatic disease.
  • Thirteen patients received adjuvant chemotherapy and/or radiation therapy.
  • At last known follow-up, seven patients died with tumor (12 to 132 months follow-up).
  • Five additional patients died, two without tumor at 36 and 72 months follow-up and three patients in whom the tumor status at death was not known.
  • Seven patients were alive with evidence of tumor (1 to 120 months) and five patients were alive without evidence of tumor (12 to 84 months).
  • High cyclin D1 LIs may be reflective of a tendency to accumulate cyclin D1 protein; however, there appears to be a block in the effect of cyclin D1 on cell proliferation in these tumors.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / analysis. Chordoma / pathology
  • [MeSH-minor] Adult. Aged. Apoptosis Regulatory Proteins. Carrier Proteins / analysis. Cranial Fossa, Posterior / pathology. Cyclin D1 / analysis. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. Lumbosacral Region / pathology. Male. Middle Aged. Retrospective Studies. Skull Base Neoplasms / mortality. Skull Base Neoplasms / pathology. Skull Base Neoplasms / therapy. Survival Analysis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12170453.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Ki-67 Antigen; 0 / TP53BP2 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


93. Sade B, Prayson RA, Lee JH: Gliosarcoma with infratemporal fossa extension. Case report. J Neurosurg; 2006 Dec;105(6):904-7
Genetic Alliance. consumer health - Gliosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliosarcomas are bimorphic intraaxial tumors.
  • Involvement of the skull base is highly unexpected.
  • This 55-year-old man presented with a 1-month history of severe progressive headache.
  • The tumor consisted of intraaxial, intracranial as well as extradural, and extracranial components with extension to the posterolateral wall of the sphenoid sinus.
  • Radiotherapy and chemotherapy consisting of temozolomide were administered subsequently, and the patient was recurrence free 12 months after his initial diagnosis.
  • Aggressive resection should be attempted, including the use of skull base surgical techniques to ensure an optimal outcome.
  • The effect of skull base involvement to the overall treatment and outcome of patients with gliosarcomas would be difficult to determine given the rare occurrence of these lesions in such locations.
  • [MeSH-major] Cranial Fossa, Middle / surgery. Gliosarcoma / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base Neoplasms / surgery. Sphenoid Sinus / surgery. Temporal Lobe / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405263.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins
  •  go-up   go-down


94. Kanouni L, Kebdani T, El Ghazi EA, El Mostarchid B, Amarti A, Mansouri A, Errihani H, Benjaafar N, El Gueddari BK: [Primitive intracranial adenoid cystic carcinoma. A case report]. Neurochirurgie; 2003 Mar;49(1):39-43
Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 50-year-old woman presenting a primitive adenoid cystic carcinoma of the middle part of skull base diagnosed by transphenoidal biopsy.
  • She was treated by exclusive radiation therapy with cobalt 60 1.25 MeV and the dose received was 66 Gy in 33 fractions.
  • Our patient remains alive 50 months after the completion of treatment.
  • Adenoid cystic carcinoma is a slow growing malignant tumor with perineural invasion which arises more frequently from salivary glands.
  • The best treatment is radical surgery followed by radiotherapy.
  • Chemotherapy is rarely used.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12736579.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


95. Haddad H, Benchakroun N, Sahraoui S, Benider A: [Osteosarcoma of the skull base: a case report]. Neurochirurgie; 2007 Dec;53(6):483-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteosarcoma of the skull base: a case report].
  • [Transliterated title] L'ostéosarcome de la base du crâne. A propos d'un cas.
  • Osteosarcoma, usually observed in long bones, is the second most frequent primitive malignant bone tumor after myeloma.
  • The skull base is an exceptional localization.
  • We report a case of skull base osteosarcoma managed in our department.
  • Cranial magnetic resonance imaging showed a voluminous mass in the skull base extending to the nasosinusal area.
  • A rhinoseptal surgical approach was used but the tumor was so huge that excision was impossible.
  • Search for extension (chest computed tomography and abdominal ultrasonography) was negative.
  • Chemotherapy was to be delivered before combination chemoradiotherapy but the patient died before any treatment could be started.
  • Osteosarcoma of the skull base is very rare.
  • The treatment is based on surgery which should be as complete as possible followed by chemoradiotherapy.
  • [MeSH-major] Osteosarcoma / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Blindness / etiology. Combined Modality Therapy. Epistaxis / etiology. Fatal Outcome. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061213.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


96. Lee JI, Kim YZ, Lee EH, Kim KH: Skull base invasion of adenoid cystic carcinoma of the lacrimal gland : a case report. J Korean Neurosurg Soc; 2008 Oct;44(4):273-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull base invasion of adenoid cystic carcinoma of the lacrimal gland : a case report.
  • Although adenoid cystic carcinoma (ACC) of the lacrimal gland is a rarely encountered orbital tumor, it invades intracranially more frequently than carcinomas of other glands in the head and neck.
  • A 52-year-old man underwent orbital exenteration and resection of intracranially extended tumor via a fronto-orbito-zygomatic approach in combination with a transfacial approach.
  • Histopathologically, the tumor showed perineural, vascular, and lymphatic invasion.
  • Additionally, he received radiotherapy (60 Gy) and adjuvant systemic cisplatin and 5-fluorouracil chemotherapy due to residual tumor in the orbit and systemic metastases (lung, ribs, and spines).
  • He was free of progression and recurrence at 6 months after treatment.
  • The authors report a case of skull base invasion by an ACC of the lacrimal gland to remind neurosurgeons planning intervention that this disease shows a tendency to invade intracranially.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2005 Mar;41(3):328-35 [15743696.001]
  • [Cites] Brain Tumor Pathol. 2000;17(3):159-63 [11310924.001]
  • [Cites] Arch Ophthalmol. 1998 May;116(5):613-6 [9596497.001]
  • [Cites] Arch Ophthalmol. 1998 Mar;116(3):315-21 [9514484.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):867-9 [8922205.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1105-12; discussion 1112-3 [8727139.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):401-7 [1320924.001]
  • [Cites] Ear Nose Throat J. 1991 Apr;70(4):218-22 [1651839.001]
  • [Cites] Can J Ophthalmol. 1982 Feb;17(1):3-9 [6282425.001]
  • [Cites] Br J Ophthalmol. 1979 Sep;63(9):600-6 [486378.001]
  • [Cites] Am J Ophthalmol. 1975 Jan;79(1):53-5 [162900.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1079-85, viii [11728933.001]
  • [Cites] Br J Plast Surg. 2001 Jul;54(5):467 [11428792.001]
  • [Cites] Pathol Int. 1998 Dec;48(12):981-4 [9952343.001]
  • (PMID = 19096692.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588318
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Metastasis / Prognosis / Skull base
  •  go-up   go-down


97. Jansen EP, Keus RB, Hilgers FJ, Haas RL, Tan IB, Bartelink H: Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys; 2000 Aug 1;48(1):27-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine the contribution of debulking surgery on local control and survival in paranasal sinus tumors.
  • As most patients present with locally advanced disease, the possibility of radical surgery is limited.
  • METHODS AND MATERIALS: Between 1977 and 1996, 73 patients (50 male: 23 female) with a paranasal sinus carcinoma were treated.
  • Treatment consisted of surgery only in 3, chemotherapy only in 1, radiotherapy only in 18, both surgery and radiotherapy in 50 patients.
  • One patient did not receive any treatment at all.
  • Three patients had concurrent chemotherapy.
  • However, combination treatment gave significantly better 5-year overall survival (OS) (60% vs. 9%; p = 0.001) and 5-year disease-free survival (DFS) (53% vs. 6%; p < 0. 0001).
  • Cox-regression analysis showed that pathologic N status (p = 0.04), palliative intention of treatment (p = 0.018), clinical orbital invasion (p = 0.003), and orbital wall invasion (p = 0.003) were parameters significantly associated with poor local control.
  • Total radiation dose of greater than 65 Gy (p = 0.05) and treatment consisting of radiotherapy alone (p = 0.002) were associated with worse overall survival; for disease-free survival clinical orbital invasion (p = 0.0005), age of greater than 65 years (p = 0.013) and pathologic T4 classification (p = 0.002) were significant factors for an unfavorable outcome.
  • In 19 of 73 patients, 26 serious (mainly ophthalmological) complications were reported; in the majority of these, the visual tract was (partly) included in the treatment fields because of tumor extension.
  • To analyze on which basis patients were selected for the combination therapy, a logistic regression was performed, concluding that clinical T4 classification (p = 0.05), radiological evidence of skull base invasion (p = 0.005), age of greater than 65 years (p = 0.026), radiological evidence of nasopharynx invasion (p = 0.02), clinical suspicion of palate invasion (p = 0.02), and radiological evidence of skin invasion (p = 0.009) were associated with choosing radiotherapy alone.
  • Patient selection, based on clinical and radiological impression of tumor extension, was the main factor explaining these favorable results.
  • We favor this combination regimen because the surgery gives quick relief of complaints and, at the same time, offers an excellent histologically proven staging method, enabling radiotherapy to be adjusted to the involved sites, thereby decreasing the risk of complications.
  • This can all be achieved with a very low orbital exenteration rate.
  • [MeSH-major] Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cause of Death. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Radiation Injuries / therapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10924968.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


98. König M, Mork J, Hall KS, Osnes T, Meling TR: Multimodal treatment of osteogenic sarcoma of the jaw. Skull Base; 2010 May;20(3):207-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment of osteogenic sarcoma of the jaw.
  • Osteosarcomas (OSs) account for 40 to 60% of primary malignant bone tumors.
  • Investigation showed high-grade OS of the right mandibular coronoid process, affecting the mandibular nerve, middle cranial fossa, internal jugular vein, and internal carotid artery (ICA).
  • True en bloc resection was performed after upfront adjuvant chemotherapy.
  • The ICA was trap-ligated intradurally, whereafter the floor of the middle fossa, including the mandibular nerve and the glenoid fossa, was detached from the skull base in one piece.
  • Subsequently, a hemimandibulectomy, total parotidectomy, ICA sacrifice, and removal of the pterygoid plates and muscles were performed, and the abovementioned structures were removed as a solitary specimen, including the facial nerve branches overlying the tumor.
  • He has no tumor recurrence 26 months after surgery.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2008 Oct;63(4):651-60; dicussion 660-1 [18824944.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Oct;72(4):444-8 [1923444.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Sep;64(3):302-7 [2443891.001]
  • [Cites] J Neurosurg. 1985 May;62(5):667-72 [3989589.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):56-61 [9001266.001]
  • [Cites] Oral Oncol. 2001 Oct;37(7):545-7 [11564573.001]
  • [Cites] Laryngoscope. 1999 Jun;109(6):964-9 [10369291.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):572-6 [6932821.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):374-6 [7719220.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Jun;26(3):191-7 [9180229.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Jun;26(3):198-204 [9180230.001]
  • [Cites] Head Neck. 1997 Sep;19(6):513-23 [9278760.001]
  • [Cites] J Otolaryngol. 2004 Jun;33(3):139-44 [15841989.001]
  • [Cites] Oral Oncol. 2008 Mar;44(3):286-94 [17467326.001]
  • [Cites] Head Neck. 2008 Aug;30(8):1020-6 [18383528.001]
  • (PMID = 21318040.001).
  • [ISSN] 1532-0065
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3037111
  • [Keywords] NOTNLM ; Osteosarcoma / craniofacial surgery / en bloc resection / jaw tumor / tumor of the skull base
  •  go-up   go-down


99. Aribas BK, Cetindag F, Ozdogan Z, Dizman A, Demir P, Unlu DN, Yologlu Z: Nasopharyngeal carcinomas: prognostic factors and treatment features. J Egypt Natl Canc Inst; 2008 Sep;20(3):230-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinomas: prognostic factors and treatment features.
  • PURPOSE: We retrospectively evaluated the clinical, radiological and pathological features determining the prognosis of patients with nasopharyngeal carcinoma in Ankara Oncology Hospital, Turkey.
  • All imaging data including CT and MRI were reevaluated according to the criteria which determine parapharyngeal, oropharyngeal, nasal, skull-base (bone)/sinus, infratemporal fossa, orbit, intracranial involvements and lymph node metastasis by our radiologists.
  • The patients were restaged using the AJCC 2002 classification with these new radiological findings and clinical data base.
  • Gender, age (40-year cut-off), histology, T- and N-stage, tumor size, regional involvement, radiotherapy and/or chemotherapy and response to therapy were studied as variables.
  • RESULTS: Five-year disease-free and overall survival rates were 45 +/- 4 % and 72 +/- 3 % , respectively.
  • We found that age, gender, WHO type, radiotherapy and/or chemotherapy, N-stage and response to therapy were significant prognostic factors on disease-free survival and overall survival.
  • In the chemo-radiotherapy group, we did not detect any survival difference between patients given four or fewer chemotherapy courses.
  • CONCLUSIONS: Radiotherapy improved survival but chemotherapy, in the neoadjuvant and adjuvant setting, had no added effect to radiotherapy.
  • N-stage and response to treatment were the most important independent predictors on survival.
  • Age, gender, type, therapy and bone/sinus involvement were among the predictive factors on multivariate analysis, as well.
  • KEY WORDS: Nasopharyngeal carcinoma - Prognostic factor - MRI - CT - Radiotherapy - Chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20424653.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


100. Güneş M, Günaldi O, Tuğcu B, Tanriverdi O, Güler AK, Cöllüoğlu B: Intracranial chondrosarcoma: a case report and review of the literature. Minim Invasive Neurosurg; 2009 Oct;52(5-6):238-41
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for intracranial chondrosarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Chondrosarcoma is a rare malignant tumor originating from cartilagenous tissue.
  • Skull radiography revealed a radioopaque lesion in the right parieto-occipital region.
  • Cranial computed tomography and magnetic resonance imaging showed a mass lesion including calcification areas and homogenous contrast enhancement in the right parieto-occipital region.
  • The tumor was removed totally by a microsurgical technique.
  • A classical type chondrosarcoma was confirmed histopathologically.
  • Primary intracranial chondrosarcomas, constitute only less than 0.16% of all brain tumors.
  • Most of them are located at the skull base.
  • Meningiomas, solitary fibrous tumor, chordoma, hemangiopericytoma, metastasis and vascular malformations should be considered as differential diagnoses.
  • Radical surgical removal of the tumor is the preferred management procedure.
  • Chemotherapy and radiotherapy may by added as adjuvant therapy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Chondrosarcoma / diagnosis. Chondrosarcoma / surgery
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Neurosurgical Procedures. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077365.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 26
  •  go-up   go-down






Advertisement